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The goal of my Ph. D. research is to develop a precisely size-controlled drug conjugated 
silica nanoparticles as a new type of drug delivery system for improved cancer therapy. 
By using such monodisperse, drug-containing NPs with discrete and incremental 
difference in sizes, my aim is to study and elucidate the existing relationships among 
particle size, biologic processing, and therapeutic functionality and to identify the optimal 
size of nanomedicine for the highest anticancer efficacy. I developed a novel drug 
delivery platform based on drug-silica nanoconjugates (drug-NCs) that can be 
controllably fabricated with nearly any desired sizes between 20 and 200 nm, with 
extremely narrow particle size distribution (less than 10% coefficient of variation), and 
10-20% drug loading and controlled drug release profile. These drug-NCs can be easily 
prepared on a gram scale also with perfectly controlled size and monodisperse size 
distribution. The in vitro and in vivo studies using these size-controlled drug-NCs 
demonstrated that particles of smaller sizes (≤50nm) are more efficient in bypassing the 
systemic, tissue, and cellular barriers, the three physiological barriers that are critical for 
effective drug delivery for cancer treatment. Interestingly, the drug-NC of 50 nm showed 
enhanced efficacy for inhibiting both primary tumor growth and tumor metastasis in 
breast cancer models in vivo. Further application of using the size controlled dual-modal 
silica NCs for targeted imaging of metastatic lymph nodes was studied. By demonstrating 
the long term safety in preliminary toxicology studies and addressing several 
formulation/development issues (e.g. salt-stability, scalability and lyophilizability, etc.), I 
developed a potentially clinically applicable, silica based drug-NCs with the optimized 
size for cancer therapy. My Ph.D. research not only helps establish the design criteria of 
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nanomedicine for cancer therapy, but also offers a solution to improve anticancer efficacy 
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1.1.1. Nanomedicines for cancer therapy 
Nanomedicine, a field that applies nanotechnology into medical applications, has been 
developed rapidly in the last 2-3 decades.1-4 It involves the design and synthesis of drug 
delivery vehicles in the size range of 1-200 nm that can carry sufficient drug, efficiently 
cross physiological barriers to reach disease sites, and cure diseases with improved 
efficacy and reduced side effects compared to conventional treatment. Nanomedicines are 
of particular interest for cancer diagnosis and treatment mainly because of the passive 
cancer targeting through the so-called Enhanced Permeation and Retention effect (EPR 
effect).5-7 The EPR effect refers to the preferential accumulation of nanoparticles (NPs) in 
tumors facilitated by the highly permeable nature of tumor vasculatures and the poor 
lymphatic drainage of the interstitial fluid surrounding the tumor.8 Clinical results have 
suggested that nanomedicines have tremendous therapeutic and diagnostic potential, 
owing to more specific targeting to tumor tissues via improved pharmacokinetics and 
pharmacodynamics, and active intracellular delivery.2, 9-12 A number of nanomedicines 
have reached clinical trials since the mid-1980s; the first sets of nanomedicines were 
approved for clinical use in the mid-1990s.2, 13  
 
1.1.2. Size effect of nanomedicine on cancer therapy 
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Although nanomedicine is promising for cancer therapy, facilitating its translation from 
bench to clinic has proven very difficult.3 Numerous nanomedicine platforms have been 
investigated as new modalities for cancer treatment, but few have been clinically 
evaluated and even fewer have been approved for clinical applications.14 The major 
reasons include the ineffectiveness of bypassing physiological barriers (ex. marginally 
improved tumor accumulation as compared to small molecule drug, poor tumor tissue 
penetration and ineffective cellular internalization by cancer cells), poorly controllable 
formulation process (ex. low drug loading, ill-defined chemistry, lack of necessary 
scalability for manufacturing practice) and undesirable toxicity (ex. use of 
immunostimulatory components, nephrotoxicity and heptotoxicity).  
 
To design and develop a successful nanomedicine with translational promise, it is crucial 
to understand the correlation between the physicochemical properties of nanomedicine 
and its biological performance in order to efficiently overcome the biological barriers.15 
There has been increasing interest in examining this relationship with some important 
findings being reported recently. For example, it was found that the shape of polymeric 
micelle greatly impacts its blood circulation time16 and that the surface charge of gold NP 
strongly affects the its tissue penetration behavior.17 Size, as one of the most important 
physicochemical properties, is also expected to greatly impact the biological response of 
nanomedicine. It was reported that the cutoff pore sizes of tumor vessel were somewhere 
between 380 and 780 nm, depending on the tumor models and microenvironments.7 Early 
studies indicated that macromolecules of a certain molecular weight range (15,000-
70,000 Da) could effectively accumulate in a solid tumor.6 It is expected that 
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nanomedicine with a certain size (or size range) can maximize such passive tumor 
targeting through the EPR effect. Accumulating evidences have demonstrated that 
particle size plays a vital role in controlling systemic and lymphatic biodistribution, in 
vivo tumor targeting and penetration, and cellular trafficking of particulate drug delivery 
vehicles.14, 15, 18-29 For instance, Tseng and his team reported that 30-nm gold NPs were 
able to drain into the local auxiliary lymph nodes with high efficiency after footpad 
administration of NPs while the 100-nm NPs were nearly undetectable in these tissues.30 
Chan and his co-workers reported that 20-nm and 60-nm gold NPs, as model drug 
delivery systems, permeate tumor tissues much more rapidly than 100-nm particles in 
vivo.18 Similar results were also reported by Pun and coworkers.31 Jing et al. reported that 
40-50 nm NPs outperform NPs of other size range for altering signaling processes that 
regulate various cellular functions.24 However, it is not clear what is the optimal size or 
size range of nanomedicine which facilitates the most efficient cancer targeting and 
highest antitumor efficacy. 
 
1.1.3. Development of silica based nanomedicine 
Among all the nanoparticulate drug delivery vehicles, numerous organic materials based 
nanocarriers, such as liposomes, polymer-drug conjugates, polymeric micelles and NPs, 
have been extensively studied for systemic cancer therapy. Each of these systems has its 
own advantages and disadvantages. For example, high drug loadings have been achieved 
with liposomes,32 but their intrinsic chemical stability is relatively low, especially under 
harsh physiological conditions. In addition to these polymer- or lipid-based 
nanomedicines, inorganic materials constructed systems, exemplified by gold NPs, 
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quantum dots, silica NPs, iron oxide NPs and carbon nanotubes, have emerged as 
promising alternatives to organic NPs for a wide range of biomedical applications. Of 
various materials being explored, silica NPs attract great interest because of the 
advantages they offer. For example, silica NPs have excellent control over NP size, 
intrinsic hydrophilic surface for increased blood circulation, good biocompatibility of 
amorphous silica, versatile functionalization chemistry, and ease of large-scale 
preparation at low cost. These unique features make silica NPs ideal candidates for the 
development of nanomedicines.  
 
Silica NPs have been used in various drug and gene delivery applications.33-56 These 
Silica NPs can be categorized as mesoporous or nonporous (solid) silica NPs. 
Mesoporous silica NPs characterized by the mesopores (2-50 nm pore size) in NPs, are 
utilized to deliver active payload based on physical or chemical absorbance.57, 58 The 
release of payloads from mesoporous silica NPs can be well controlled using the 
“gatekeeper” strategy.58 Mesoporous silica NPs have been extensively explored for the 
encapsulation and delivery of chemotherapeutics.40, 42, 43, 47-49, 54, 56, 59-61 In contrast, 
nonporous silica NP delivery cargos through encapsulation or conjugation and the release 
profile of payloads are controlled by chemical linkers. Especially the conjugation strategy 
allows for the high incorporation efficiency of drug and high drug loading. Nonporous 
silica NPs were first used to conjugate with photosensitizer for photodynamic therapy.53 
For example, Schoenfisch group reported the unique nitric oxide (NO)-releasing silica 
NPs with controlled NP sizes.62 These NO-releasing nanoparticles exhibited enhanced 
growth inhibition of ovarian tumor cells when compared to both control nanoparticles 
5 
 
and a previously reported small molecule NO donor, PYRRO/NO. In addition, the NO-
releasing nanoparticles showed greater inhibition of the anchorage-independent growth of 
tumor-derived and Ras-transformed ovarian cells.63 Bleomycin-A5, an anticancer drug 
that chelates metals such as FeII and catalyzes the formation of single-stranded or double-
stranded DNA lesions in the presence of oxygen, was also conjugated to silica NP to 
surface and maintained its cytotoxicity.64 As compared to mesoporous silica NP, 
nonporous silica NPs have the advantages of excellent size control and ease of synthesis. 
In particular, the size controlled formulation process typically does not require any 
additives (e.g., surfactant), minimizing the concern of involving non-biocompatible 
components in the silica NPs. Thus, by taking advantage of these unique properties of 
non-porous silica NPs, one can possibly construct biocompatible silica based, precisely 
size controlled nanomedicine with conjugated chemotherapeutic that is releasable.  
 
1.2. Scope and Organization 
The aim of my Ph. D. research is to develop size precisely controlled, drug conjugated 
silica nanoparticles as a new type of drug delivery system for improved cancer therapy. 
In the following five chapters, I will describe both the fundamental investigations of the 
size effect of nanomedicine in biological systems and the unremitting efforts of driving 
this silica based drug delivery system for potential clinical application.  
 
The organization of my thesis is briefly described below (Figure 1.1). Chapter 2 describes 
the details of the synthesis and formulation studies of the precisely size controlled drug-
silica nanoconjugates. With such an excellently size-controlled nanomedicine developed, 
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I have systematically investigated the size effect on its performance of overcoming 
physiological barriers as describe in Chapter 3. In Chapter 4, the size impact of silica 
NCs on the overall efficacy in both primary and metastatic tumor models is discussed. 
Chapter 5 shows the further development of the size controlled silica NCs for the 
application in diagnosis of tumor metastasis. The last chapter, Chapter 6, focuses on the 
investigation of the long-term biocompatibility of the silica NCs. 
 
 
Figure 1.1 Organization of the dissertation. 
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CHAPTER 2  




Nanomedicines in the form of polymer-drug conjugates, micelles, nanoparticles (NPs) 
and vesicles have been extensively studied in the past 2-3 decades for drug and gene 
delivery applications.1-9 Although promising, the clinical translation of nanomedicines 
has proven very difficult.3 Numerous studies have been designed and performed using 
nanomedicine as a new modality for improved cancer treatment. However, very few 
nanomedicines have ever been clinically evaluated and even less been approved for 
clinical cancer treatment.10, 11 Although no generalized pathway exists for the clinical 
translation of nanomedicine, there is a consensus that a clinically applicable 
nanomedicine should at least possess controlled physicochemical and pharmacological 
properties. Specifically, such nanomedicine should have controlled size with low size 
dispersity, high drug loading, high loading efficiency, controlled drug-release kinetics, 
and sufficient stability and capability of staying non-aggregated in biological media. The 
nanomedicine should also be easily manufactured at a large-scale, from grams up to 
kilograms scale, and lyophilized to form solid formulation. Very few nanomedicine 





There has been growing interest in using nanomedicines for targeted or personalized 
cancer therapy.1, 2 Accumulating evidences show that the size of nanomedicine plays a 
vital role in controlling systemic and lymphatic biodistribution, tumor targeting and 
penetration, and cellular internalization of drug delivery vehicles.12-23 NPs with size 
controlled within 20-60 nm have been particularly interesting and actively pursued 
because some recent studies showed that NPs within this size range have distinct 
biodistribution, tumor penetration and cellular trafficking properties that are critical to the 
in vivo use of nanomedicine. For instance, Tseng and his team reported that 30-nm NPs 
administered via footpad were able to drain into the local auxiliary lymph nodes with 
high efficiency, while the 100-nm NPs dosed in the same manner were nearly 
undetectable in these tissues.24 Chan and his co-workers reported that 20- and 60-nm gold 
NPs, as model drug delivery systems, permeate tumor tissues much more rapidly than 
100-nm particles in vivo.25 Similar results were also reported by Pun and coworkers.26 
Jing et al. reported that 40~50-nm NPs outperformed NPs in different size ranges for 
altering signaling processes that regulate various cellular functions.15 
 
Nanomedicines are typically prepared through bottom-up approaches, such as self-
assembly of amphiphilic copolymers for the preparation of micelles or vesicles, and 
nanoprecipitation of hydrophobic polymers for the preparation of NPs. The micellation, 
vesiclization and nanoprecipitation methods certainly allow for facile preparation of 
nanomedicines at a large scale. However, the drawbacks of these formulation methods 
are also obvious; the resulting micelles, vesicles or NPs often have broad particle size 
distributions, and variable, sometimes uncontrolled drug loading and release profiles. It is 
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also extremely difficult to prepare NPs with narrow or mono-dispersity in size controlled 
within 100 nm using these conventional technologies. There were even less reports of the 
in vitro and in vivo properties of NPs with discrete size less than 50 nm.13, 15, 24, 25, 27 In 
my graduate research, I successfully conceived the idea and developed drug-silica 
conjugated NPs (Scheme 2.1), termed drug-silica nanoconjugates (drug-NCs) and 
denoted as drug(dye)X (X = particle size in nm).  Remarkably, drug-NCs can be 
formulated at nearly any size, ranging from 20 nm to 200 nm with monodisperse size 
distributions (less than 10% coefficient of variation (CV), the ratio of the standard 
deviation  to the mean  of particle size), 10-20% drug loading and controlled drug 
release profiles. These drug-NCs can be easily prepared in large scale but still with 
perfectly controlled size and mono-disperse size distribution. By addressing several 
formulation and development issues (e.g., salt-stability, scalability and lyophilizability, 
etc.), I developed a potentially clinically applicable drug(dye) delivery nanomedicine 
platform that can be precisely controlled formulated at any size between 20 and 200 nm 
on large scale.  
 
2.2. Materials and Methods 
2.2.1. General 
All chemicals including tetraethyl orthosilicate (TEOS, 99.999%), pyrenemethanol (Pyr-
OH) and camptothecin (Cpt) were purchased from Sigma-Aldrich (St Louis, MO, USA) 
and used as received unless otherwise noted. mPEG5k-triethoxysilane (mPEG-sil, 6) (Fig. 
1) was purchased from Laysan Bio (Arab, AL, USA) and used as received. All anhydrous 
solvents were purified by passing them through dry alumina columns and kept anhydrous 
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using molecular sieves. The low resolution electrospray ionization mass spectrometry 
(LR-ESI-MS) experiments were performed on a Waters Quattro II Mass Spectrometer. 
Matrix Assisted Laser Desorption/Ionization-Time Of Flight mass spectrometry 
(MALDI-TOF MS) spectra were collected on an Applied Biosystems Voyager-DETM 
STR system. HPLC analyses were performed on a System Gold system (Beckman 
Coulter, Fullerton, CA, USA) equipped with a 126P solvent module, a System Gold 128 
UV detector and an analytical C18 column (Luna C18, 250 × 4.6 mm, 5 μm, 
Phenomenex, Torrance, CA, USA). The NMR experiments were conducted on a Varian 
U500, a VXR500 or on a UI500NB (500 MHz) NMR spectrometer. The sizes and 
monodispersities of silica particles were determined on a Hitachi S4800 high resolution 
Scanning Electron Microscope (SEM). The real time monitoring of the drug(dye)-silica 
NC sizes and monodispersities were done by ZetaPlus dynamic light-scattering (DLS) 
detector (15 mW laser, incident beam = 676 nm, Brookhaven Instruments, Holtsville, NY, 
USA). The solid forms of NCs were obtained by lyophilizing the NC/lyoprotectant 
solution using a Freezone benchtop lyophilizer (Fisher Scientific, Fairland, NJ, USA).  
 
2.2.2. Synthesis of pyrenemethyl 2-((3-(trimethoxysilyl)propyl)thio)acetate (Pyr-sil, 1, 
Scheme 2.1)  
 
Synthesis of pyrene-1-ylmethyl 2-bromoacetate (Pyr-Br): Pyrenemethanol (109.6 mg, 




mmol) and 2-bromoacetyl bromide (132.2 L, 1.50 mmol) in 1-mL dichloromethane. The 
mixture was stirred at room temperature (RT) for 17 h. After the solvent was evaporated, 
the crude product was purified by silica gel column (hexane/EtOAc = 2/1) to give 167-
mg final product as a yellow solid (90% yield). 1H-NMR (CDCl3, 500 MHz):  8.28-8.03 
(m, 9H, ArH), 5.94 (s, 2H, ArCH2), 3.90 (s, 2H, CH2Br). ESI (m/z): calcd for C19H13BrO2, 
353.2 [M]; found, 375.9 [M+Na]+.  
 
Synthesis of pyrenemethyl 2-((3-(trimethoxysilyl)propyl)thio)acetate (1, Scheme 2.1): 
Pyr-Br (40.2 mg, 0.11 mmol) in anhydrous DMF (0.5 mL) was treated with anhydrous 
TEA (180 L, 1.29 mmol) and (3-mercaptopropyl)trimethoxysilane (210 L, 1.10 mmol). 
The mixture was stirred at RT for 11 h. After the solvent was evaporated, the crude 
product was purified by silica gel column (hexane/EtOAc=3/1) to give final product 1. 
HPLC purity: >95%. 1H-NMR (CDCl3, 500 MHz):  8.31-8.03 (m, 9H, ArH), 5.91 (s, 2H, 
ArCH2), 3.51 (s, 9H, (CH3O)3Si), 3.29 (s, 2H, CH2Br), 2.62 (t, 2H, SCH2), 1.67 (m, 2H, 
CH2), 0.65 (t, 2H, CH2Si). 13C-NMR (CDCl3, 500 MHz):  170.99, 132.09-121.49, 65.75, 
50.80, 41.96, 35.75, 33.74, 22.63. ESI (m/z): calcd for C25H28O5SSi, 468.6 [M]; found, 
469.2 [M+H]+. 
 




Synthesis of Cpt-Br: Cpt (10.4 mg, 0.030 mmol) was suspended in anhydrous 
dichloromethane (0.5 mL) followed by the addition of 4-dimethylaminopyridine (0.4 mg, 
0.003 mmol), bromoacetic acid (30 mg, 0.18 mmol) and diisopropylcarbodiimide (26 L, 
0.18 mmol). The mixture was stirred at RT for 24 h. The reaction was monitored by 
HPLC. After the solvent was evaporated in vacuum, the crude product was purified by 
silica column (CH2Cl2/MeOH=100/1) to give Cpt-Br as shown above. 1H-NMR (CDCl3, 
500 MHz):  8.40 (s, H), 8.22 (d, H), 7.94 (d, H), 7.84 (t, H), 7.67 (t, H), 7.28(s, H), 5.70 
(d, H), 5.42 (d, H), 5.30 (s, 2H), 3.84 (m, 2H), 2.32 (q, H), 2.20 (q, H), 1.00 (t, 3H).  13C-
NMR (CDCl3, 500 MHz):  167.07, 166.21, 157.51, 152.05, 149.18, 146.79, 145.14, 
131.40, 130.91, 129.99, 128.66, 128.45, 128.42, 128.32, 120.64, 95.93, 88.63, 67.46, 
50.22, 32.07, 25.19, 7.77. HPLC purity: >95%. MALDI (m/z): calcd for C22H17BrN2O5, 
469.3, [M]; found, 470.1 [M+H]+.  
 
Synthesis of Cpt-S-sil (2): Cpt-Br (6.5 mg, 0.014 mmol) was dissolved in anhydrous 
DMF (0.5 mL). TEA (9 L, 0.07 mmol) and (3-mercaptopropyl)trimethoxysilane (4 L, 
0.021 mmol) were added. The reaction mixture was stirred at RT for 3h. After the solvent 




(CH2Cl2/MeOH=100/1). 1H-NMR (CDCl3, 500 MHz):  8.40 (s, H), 8.21 (d, H), 7.94 (d, 
H), 7.82 (t, H), 7.66 (t, H), 7.35(s, H), 5.68 (d, H), 5.40 (d, H), 5.29 (s, 2H), 3.47 (s, 9H), 
2.84 (s, 2H), 2.65 (t, 2H), 2.28 (q, H), 2.17 (q, H), 1.68 (q, 2H), 0.99 (t, 3H), 0.75 (t, 2H). 
13C-NMR (CDCl3, 500 MHz):  169.41, 167.49, 157.59, 152.57, 149.14, 146.57, 145.90, 
131.38, 130.86, 129.96, 128.68, 128.42, 128.26, 120.39, 110.01, 96.19, 88.63, 67.30, 
50.20, 46.25, 42.39, 35.54, 31.95, 23.74, 22.36, 7.85. HPLC purity: >95%. ESI (m/z): 
calcd for C28H32N2O8SSi, 584.7 [M]; found, 585.3 [M+H]+, 607.3 [M+Na]+. 
 
2.2.4. Synthesis of Cpt-NH-sil (3, Scheme 2.1)  
 
Cpt-Br (6.5 mg, 0.014 mmol) (from the synthesis of Cpt-S-sil) was dissolved in 
anhydrous DMF (0.5 mL). TEA (9 L, 0.07 mmol) and (3-aminopropyl)trimethoxysilane 
(4 L, 0.021 mmol) were added.  The reaction mixture was stirred at RT for 3h. After the 
solvent was evaporated in vacuum, the crude product was purified by preparative TLC 
(CH2Cl2/MeOH = 100/1) to give 7 in 70% yield. 1H-NMR (CDCl3, 500 MHz):  8.40 (s, 
H), 8.20 (d, H), 7.94 (d, H), 7.82 (t, H), 7.65 (t, H), 7.20 (s, H), 5.66 (d, H), 5.40 (d, H), 
5.28 (s, 2H), 3.73 (q, 6H), 3.58 (s, 2H), 2.66 (t, 2H), 2.28 (q, H), 2.16 (q, H), 1.63 (m, 
2H), 1.20 (t, 9H), 0.96 (t, 3H), 0.63 (t, 2H). 13C-NMR (CDCl3, 500 MHz):  172.05, 




128.28, 120.54, 96.23, 76.44, 67.38, 58.87, 52.38, 50.44, 47.97, 31.68, 23.17, 18.50, 7.77. 
ESI (m/z): calcd for C31H39N3O8Si 609 [M]; found, 610.3 [M+H]+. 
 
2.2.5. Synthesis of paclitaxel containing silane (Ptxl-sil, 4, Scheme 2.1)  
 
Synthesis of Ptxl-Br: Paclitaxel (Ptxl, 19.8 mg, 0.023 mmol) in anhydrous THF (1.0 mL) 
was treated with anhydrous TEA (16.1 L, 5 eq.) and 2-bromoacetyl bromide (4.7 mg, 
0.023 mmol) in 0.1-mL dichloromethane at RT for 24 h. After the solvent was 
evaporated, the crude product was purified by preparative TLC (hexane:EtOAc, 1:2 v/v).  
HPLC purity: >95%. MALDI (m/z): calcd for C49H52BrNO15, 974.8 [M]; found, 998.8 
[M+Na]+.  
 
Synthesis of Ptxl-sil (3): Ptxl-Br (18.2 mg, 0.019 mmol) in anhydrous DMF (1 mL) was 
treated with TEA (anhydrous, 12 L, 0.095 mmol, 5 eq.) and 3-
mercaptopropyl)trimethoxysilane (10 L, 0.057 mmol, 3 eq.) at RT for 12 h. After the 
solvent was evaporated, the crude product was purified by prep TLC (hexane:EtOAc 
=1:2 v/v) to give 3 in 62% yield. HPLC purity: >95%. ESI (m/z): calcd for 





2.2.6. Synthesis of docetaxel containing silane (Dtxl-sil, 5, Scheme 2.1) 
 
Synthesis of Dtxl-Br: Docetaxel (10.0 mg, 0.012 mmol) in 0.5 mL DMF (anh) was treated 
with 8.6 L TEA (anh, 5 eq.), 4-Dimethylaminopyridine (0.2 mg, 0.0016 mmol) and 2-
bromoacetyl bromide (15 mg, 0.074 mmol) in 0.1 mL dichloromethane at RT for 12 h. 
After the solvent was evaporated, the crude product was purified by prep TLC 
(Hex/EtOAc=3/2).  HPLC purity: >95%. MALDI: 1072.7, [M+Na]+. 
 
Synthesis of Dtxl-sil (5): Dtxl-Br (3.4 mg, 0.0032 mmol) in 0.5 mL DMF (anh) was 
treated with 5 L TEA (anh) and 2 L (0.010 mmol) (3-Mercaptopropyl)trimethoxysilane 
at RT for 3 h. After the solvent was evaporated, the crude product was purified by prep 
TLC (Hex/EtOAc=1/2). HPLC purity: >95%. ESI: 1303.0, [M+Na]+. 
 
2.2.7. Synthesis of rhodamine B isothiocyanate (RITC) containing silane (RTIC-sil, 6, 





In a reaction vial containing 3-aminopropyltrimethoxysilane (30 mg, 0.173 mmol) was 
added an anhydrous ethanol solution (1 mL) of RITC (17 mg, 0.032 mmol) and 
triethylamine (14.5 mg, 0.144 mmol). The reaction mixture was stirred for 12 h in 
nitrogen at 50°C in dark. The solvent and unreacted triethylamine was removed by 
vacuum to give RITC-sil (4), which was used directly without further purification. 
 
2.2.8. Synthesis of infrared dye (IR783) containing silane group (IR783-sil, 7, 
Scheme 2.1) 
 
IR783 (23.5 mg, 0.031 mmol) in anhydrous DMF (1.0 mL) was treated with TEA (22 L, 
0.155 mmol, 5 eq.) and (3-mercaptopropyl)trimethoxysilane (30 L, 0.155 mmol, 5 eq.) 
at 55°C for 12 h. After the solvent was evaporated, IR783-sil (5, 80% yield) was used 
directly for the fluorescent labelling of silica nanoconjugates. HPLC purity: >80%. ESI 






























2.2.9. Synthesis of ester bond bridged silane (EBB-sil, 8, Scheme 2.1)28, 29 
 
To a solution of 1,4-butanediol diacrylate (1 g, 5.05 mmol) in anhydrous benzene (10 
mL) was added triethoxysilane (2.4 ml, 13.2 mmol) followed by the addition of 
platinum(0)-1,3-divinyl-1,1,3,3-tetramethyldisiloxane complex solution (150 µL, in 
xylene, Pt ~2 %) under the protection of N2. The resulting mixture was stirred at 50°C for 
12h. After the reaction mixture was cooled to RT, benzene (10 mL) was added. The 
solution was then passed through silica gel packed filter. The solvent and low boiling 
point contaminates of the filtrate was removed under vacuum. The residue was dried to 
give the product 8 (2.4 g, 90%). 1H-NMR (CDCl3, 500 MHz):  4.08 (t, 4H, OCH2), 3.86 
(q, 12H, SiOCH2), 2.31 (q, 4H, CH2C(O)), 1.69 (m, 4H, CH2), 1.22 (t, 18H, CH3), 1.12 (t, 
4H, SiCH2). 13C-NMR (CDCl3, 500 MHz):  174.73, 64.28, 59.45, 27.77, 25.61, 18.20, 
9.33. ESI (m/z): calcd for C22H46O10Si2, 526.8 [M]; found, 565 [M+K]+. 
 
2.2.10. Synthesis of acetal bond bridged silane (ABB-sil, 9, Scheme 1)28, 29 
 
To a solution of 3,9-divinyl-2,4,8,10-tetraoxaspiro[5.5] undecane (1 g, 4.7 mmol) in 
anhydrous benzene (10 mL), triethoxysilane (2.1 ml, 11.6 mmol) was added followed by 





(150 µL, in xylene, Pt ~2 %) under N2. The resulting mixture was stirred at 50°C for 12h. 
After the reaction mixture was cooled to RT, the benzene was added. The solution was 
then passed through a silica gel packed filter. The solvent and low boiling point 
contaminates of the filtrate was removed under vacuum. The residue was dried to give the 
product 9 (2.4 g, 93%). 1H-NMR (CDCl3, 500 MHz):  4.38 (t, 2H, OCH), 3.82 (q, 12H, 
SiOCH2), 3.53 (q, 4H, CH2O), 3.32 (d, 4H, CH2O), 1.69 (m, 4H, CH2), 1.20 (t, 18H, 
CH3), 0.70 (t, 4H, SiCH2). 13C-NMR (CDCl3, 500 MHz):  103.92, 70.79, 58.74, 32.63, 
28.25, 18.50, 4.15. ESI (m/z): calcd for C23H48O10Si2, 540.8 [M]; found, 541 [M+H]+. 
 
2.2.11. General procedure for the preparation of Pyr-silica nanoconjugates29-32 
Methanol (1.0 mL), DI water (0.27 mL) and concentrated ammonia (0.24 mL) were 
mixed. TEOS (62.5 µL, 0.28 mmol) was then added to the solvent mixture followed by 
the addition of a DMSO solution (20 µL) of 1 (2 mg, 4.3 µmol). The mixture was stirred 
at a stirring rate of 100 rpm at RT for 12 h. The resulting Pyr-NCs were collected by 
centrifugation at 15k rpm and washed by ethanol (3 × 1 mL). One drop of a dilute 
solution of silica NCs in ethanol on a silicon wafer was allowed to dry in air and then 
analysed by SEM at 5 kV. The NC size (200 nm in this case) was determined by 
averaging at least 100 particles on a representative SEM image. Fabrication of 
monodisperse Pyr-NCs with other sizes can be similarly achieved by tuning the 
concentrations of TEOS, water and ammonia (Table 2.1 and Table 2.2).  Cpt-NCs, Ptxl-
NCs, RITC-NCs and IR-NCs with monodisperse, controlled sizes were prepared under 




2.2.12. General procedure of preparing Cpt- or Ptxl-NCs via modified Stöber method33 
The silica NCs of various sizes were prepared using Stöber method as described in the 
Method section of the paper without the addition of 1. The obtained silica NCs (4.1 mg) 
were re-dispersed in a mixture of EtOH/DI water (0.7 mL/0.2 mL) followed by the 
addition of 2 (1.7 mg) in DMSO (100 L). After the mixture was stirred for 10 min, a 
NaF aqueous solution (10 mg/mL, 25 L) was added. After 12 h of reaction, 10 (10 
mg/mL, 100 µL) was added. The mixture was stirred for another 12 h. The supernatant of 
the mixture was analysed by HPLC to determine the unreacted 2 in order to determine the 
incorporation efficiency of drugs to NCs. The drug loadings were calculated based on the 
feed ratio of drugs and the incorporation efficiency. The NCs were collected by 
centrifugation at 15k rpm. The isolated NCs were washed with ethanol (3 × 1 mL) and re-
dispersed in DI water or 1× PBS buffer before use. The preparation of Ptxl-NC was 
similar except for addition of 4 (1.0 mg). 
 
2.2.13. Preparation of RITC/IR-NCs via Stöber method  
The silica NCs (27.5 mg) of various sizes were prepared as described above without the 
addition of drug(dye)-sil reagents. After the reaction was complete, without isolating the 
NCs, a methanol solution of 6 (10 mg/mL, 100 µL) was added to the silica NC solution. 
The mixture was stirred for 12 h in dark. A methanol solution of 10 (10 mg/mL, 100 µL) 
was added. RITC-NCs were collected by centrifugation at 15k rpm, washed with ethanol 
(3 × 1 mL), and re-dispersed in DI water or 1× PBS buffer before use. IR-NCs were 




2.2.14. Preparation of Cpt- or Ptxl- silica NCs using degradable silane 8 or 9 via a 
reverse micro-emulsion process 
During the NC fabrication through the reverse micro-emulsion process, Triton X-100 and 
n-hexanol were employed as the surfactant and the co-surfactant, respectively. To prepare 
20-nm Cpt-NCs containing degradable ester bond (Cpt-EB20, Table 1), cyclohexane (7.5 
mL), n-hexanol (1.8 mL) and Triton X-100 (1.77 mL) were mixed and stirred for 20 min. 
DI water (480 μL) and 8 (80 L) were added over the course of 20 minutes. Ammonia 
hydroxide (28%, 60 L) was added to initiate the reaction. After 24 h, 2 (17.9 mg, 0.03 
mmol) in dichloromethane solution (500 L) was added. The reaction solution was 
stirred for another 12 h. A methanol solution of 10 (10 mg/mL, 600 µL) was added. The 
supernatant of the mixture was analysed by HPLC to quantify the unreacted 2 in order to 
determine the incorporation efficiency of drugs to NCs. The drug loading was determined 
based on the feed ratio of 2 versus 8 and TEOS, and the incorporation efficiency of 2 to 
NC. The emulsion was disrupted by the addition of 10-mL ethanol. The NC (Cpt-EB20) 
was collected by centrifugation at 15k rpm and washed with ethanol (3 × 1 mL). Cpt-
EB50, Cpt-AB20 and Ptxl-EB20 (entries 26-29, Table 2.1) were prepared by following 
similar condition as summarized in Table 2.1 and Table 2.3.  
 
2.2.15. Preparation of Cpt-NCs in gram scale 
For the preparation of 50 nm Cpt conjugated silica NPs (with 1% loading of Cpt), 15 mL 
methanol, 5.40 mL DI water and 1.35 mL concentrated ammonia were mixed. Then 939 
µL TEOS was added to the mixture, which was stirred gently for 5h. Then 8.4 mg Cpt-S-
sil in 500 µL DMSO solution was added to the mixture. The mixture was stirred gently 
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(stirring rate was 100 rpm) at RT for 12 h. The NPs were collected by centrifugation at 15 
k rpm and washed by ethanol for three times. The NP sizes and shapes were characterized 
by SEM. 
 
2.2.16. Release kinetics 
The Cpt-NCs were dispersed in 50% reconstituted human serum (Sigma-Aldrich) (0.6 
mg/mL), equally distributed to 20 vials with 1 mL NC solution per vial, and then 
incubated at 37°C. At selected time intervals, one selected vial of each group was taken 
out of the incubator. The NC solution was mixed with equal volume of methanol (1 mL) 
and centrifuged at 15,000 rpm for 10 min. The supernatant (1 mL) was transferred to an 
Eppendorf tube without disturbing the precipitates (NCs) and tuned to pH 2 with 
phosphoric acid (85%, 100 µL). The resulting solution was directly injected into HPLC 
equipped with an analytical C18 column (Luna C18, 250 × 4.6 mm, 5 μ, Phenomenex, 
Torrance, CA, USA). A mixture of acetonitrile and water (containing 0.1% TFA) at a 
volume ratio of 1:3 was used as the mobile phase. The flow rate was set at 1 mL/min. The 
area of the HPLC peak of the released Cpt (abs = 370 nm) was intergraded for the 
quantification of Cpt as compared to a standard curve of free Cpt prepared separately. 
The Cpt release kinetic profiles from Cpt20, Cpt-N20 and Cpt-N50 were showed in 
Figure 2.8.  
 
2.2.17. Stability of PEGylated silica NCs. 
PEGylated silica NPs (1.5 mg) were dispersed in 2 mL 1× PBS. The hydrodynamic 
diameter (which is 30 nm larger than the diameter of hard cores of NPs measured by 
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SEM) of NPs were measured by DLS and followed for 4 hours. Non- PEGylated NPs 
were measured similarly as the control. 
 
2.2.18. Lyophilization of silica NPs in the presence of lyoprotectants 
Silica NPs were prepared at TEOS/10 ratio (wt/wt) of 19.6:1 using Stöber method as 
described previously (St-B and St-D) and analysed with DLS. One of the selected 
lyoprotectants (Table 2.5) was added at different lyoprotectant/NP ratio (varying from 1:1 
to 10:1 wt/wt) to the NP solution. The solution was lyophilized. The solid-form silica 
NP/lyoprotectant was reconstituted with 2-mL DI water to prepare a NP aqueous solution 
at a concentration of 10 mg/mL. The reconstituted silica NP was analysed by DLS 
(Figure 2.11).  The silica NP lyophilized in the absence of lyoprotectant and reconstituted 
with water was used as the negative control.    
 
2.3. Results and Discussion 
2.3.1. Synthesis of Pyr-silica nanoconjugates (Pyr-NCs) 
Silica NPs can be easily prepared on large scale with discrete, monodisperse particle sizes 
through the condensation reaction of tetraethyl orthosilicate (TEOS) or tetramethyl 
orthosilicate (TMOS).  For example, monodisperse silica spheres with controlled sizes 
(50 nm-2 µm) can be prepared in a reaction mixture of water, alcoholic solvent, ammonia, 
and alkyl silicate ester by controlling alcoholic solvents, different alkyl silicate esters, as 
well as the concentration of each component.30 Silane coupling agents containing a 
trialkoxysilane group can be readily incorporated into silica NPs during such 
condensation reaction.34 I reasoned that trialkoxysilane-containing drugs (dyes) through a 
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degradable ester linker should be able to be condensed with TEOS or TMOS to allow the 
drug (dye) molecules to be incorporated into the resulting silica NPs, which can be 
released through the cleavage of the ester linker. To demonstrate this concept, I started 
with 1, a trimethyl orthosilicate that contains pyrenemethanol (Pyr-OH) as the model 
drug. By carefully controlling reaction conditions, I was able to prepare Pyr-NCs with 
discrete sizes 15 nm apart between 20 nm and 80 nm. As shown in Figure 2.1a and Table 
2.1 (entry 1-5), NCs with sizes of 22.2  1.7 nm (Pyr20), 36.3  2.9 nm (Pyr35), 49.3  
2.9 nm (Pyr50), 64.1  3.1 nm (Pyr65) and 80 nm (Pyr80) can be readily prepared in 
multigram quantities. To test the reproducibility of these conditions to prepare NCs with 
the corresponding size, I repeated each experiment 3 to 5 times and found that the NCs 
with the desired size could be precisely produced each time. For instance, the five 
experiment for making Pyr20 under the same condition resulted in particles with size of 
22.2  1.7 nm, 22.7  2.4 nm, 22.9  1.9 nm, 22.2  1.1 nm and 26.2  2.4 nm (Figure 
2.1a). The CV values of these five experiments are 7.7, 10.6, 8.3, 5.0 and 9.2, 
respectively, with an average of CV value of 8.1%.  The low CV values (< 10%) of Pyr20 
NC indicate these particles are technically monodisperse by industry standard.35 The 
conditions of making pyrene-containing NCs of 35, 50, 65 and 80 nm showed similar 
control over NC size, monodispersity and reproducibility (Figure 2.1a). The 
hydrodynamic sizes of these Pyr-NCs were also measured by dynamic light scattering 
(DLS) (Table 2.4), which are larger than the hard core sizes measured by scanning 
electron microscopy (SEM). All the PDI values measured by DLS are below or around 
0.1 indicating again the high monodispersity of these Pyr-NCs. To be consistent, all NC 
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(Figure 2.1 cont.) different drug/dye-silica NCs with sizes of 50 nm and 20 nm. (c)  The SEM 
images of Cpt20 and Cpt-N20 as the examples to show the excellent size control and 
monodispersity of NCs with sizes of 20 nm. 
 




[a] Methods and subjects used for formulation are described in Scheme 1; [b] components used 
for the silica NC formulation are presented in weight ratio; [c] The volume ratio of MeOH/DI 
water/concentrated ammonia/TEOS were tuned in St method to control the NC sizes: St-A, 
32.0/11.5/2.24/1.00; St-B, 16.0/5.76/1.12/1.00; St-C, 16.0/5.76/1.28/1.00; St-D, 
16.0/5.76/1.44/1.00; St-E, 16.0/5.76/1.60/1.00; St-F, 16.0/5.76/1.76/1.00; St-G, 
16.0/4.32/3.84/1.00. Cyclohexane was used as oil phased in Trx-A and –C; decane was used in 
Trx-B; [d][e] The NC sizes were characterizes by SEM. Average diameter (D) and standard 
deviation (SD) were calculated by measuring 100 NCs in SEM images; [f] CV%=SD/D; [g] The 
incorporation efficiency (I.E.) was determined by monitoring and quantifying the concentration 
of free drugs in the supernatant using HPLC by centrifuging down the NCs; [h] Real drug loading 
Entry Name of NC Drug/Dye Formulation
[b] Method[c] D[d] (nm) SD
[e] 
(nm) CV%
[f] I.E.[g] (%) LD
[h] 
(wt%)
1 Pyr20 Pyr TEOS/1 (29.4/1) St-A 26.6 2.7 10.2 N/A N/A
2 Pyr35 Pyr TEOS/1 (29.4/1) St-B 36.3 2.9 8.0 N/A N/A
3 Pyr50 Pyr TEOS/1 (29.4/1) St-C 43.4 3.9 9.0 N/A N/A
4 Pyr65 Pyr TEOS/1 (29.4/1) St-D 64.1 3.1 4.8 N/A N/A
5 Pyr80 Pyr TEOS/1 (29.4/1) St-E 84.4 7.6 9.0 N/A N/A
6 Pyr100 Pyr TEOS/1 (29.4/1) St-F 104.4 8.8 8.4 N/A N/A
7 Pyr200 Pyr TEOS/1 (29.4/1) St-G 195.3 12.8 6.6 N/A N/A
8 PLGA-PEG90[i] N/A PLGA-PEG NPP 91.8 36.0 39.2 N/A N/A
9 Cpt20 Cpt TEOS/2/10 (2.2/1/0.14) St-A 26.3 2.5 9.5 81.2 24.0
10 Cpt50 Cpt TEOS/2/10 (2.2/1/0.14) St-C 51.5 3.8 7.4 82.9 24.0
11 Cpt100 Cpt TEOS/2/10 (2.5/1/0.14) St-F 96.1 8.8 9.2 86.5 16.9
12 Cpt200 Cpt TEOS/2/10 (2.2/1/0.14) St-G 222.7 16.5 7.4 80.7 24.0
13 Cpt-N20 Cpt TEOS/3/10 (3.8/1/0.20) St-A 25.9 2.4 9.3 79.3 15.9
14 Cpt-N50 Cpt TEOS/3/10 (3.8/1/0.20) St-C 56.2 5.2 9.3 83.2 16.6
15 Cpt-N200 Cpt TEOS/3/10 (3.8/1/0.20) St-G 197.3 15.9 8.1 81.0 16.2
16 Ptxl50 Ptxl TEOS/4/10 (8.1/1/0.40) St-C 51.8 4.9 9.5 80.7 13.4
17 Dtxl50 Dtxl TEOS/5/10 (8.1/1/0.40) St-C 55.0 5.2 9.5 67.4 14.3
18 Dtxl100 Dtxl TEOS/5/10 (8.1/1/0.40) St-F 106.9 10.0 9.4 73.1 15.4
19 RITC20 RITC TEOS/6/10 (58.8/1/3.0) St-A 23.7 2.3 9.7 N/A N/A
20 RITC50 RITC TEOS/6/10 (58.8/1/3.0) St-C 49.2 4.9 10.0 N/A N/A
21 RITC200 RITC TEOS/6/10 (58.8/1/3.0) St-G 188.9 14.4 7.6 N/A N/A
22 IR20 IR TEOS/7/10 (58.8/1/3.0) St-A 26.5 2.6 9.8 N/A N/A
23 IR50 IR TEOS/7/10 (58.8/1/3.0) St-C 47.8 4.7 9.8 N/A N/A
24 IR200 IR TEOS/7/10 (58.8/1/3.0) St-G 206.9 16.2 7.8 N/A N/A
25 Cpt50*[j] Cpt TEOS/2/10 (88.2/1/9.0) St-H 46.2 4.6 10.0 84.8 1.0
26 Cpt-EB20 Cpt 8/2/10 (6.1/1/0.3) Trx-A 23.5 2.3 9.8 87.5 13.8
27 Cpt-EB50 Cpt 8/2/10 (6.0/1/0.3) Trx-B 45.5 4.2 9.2 93.3 14.6
28 Cpt-AB20 Cpt TEOS/9/2/10(3.0/3.0/1/0.3) Trx-C 24.6 2.4 9.8 90.6 14.2
29 Ptxl-EB20 Ptxl 8/4/10 (9.0/1/0.40) Trx-A 22.7 2.2 9.7 77.4 8.8
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(Table 2.1 cont.) (LD) was calculated based on the feeding ratio of the drug to NC and I.E. value; 
[i] poly(lactide-co-glycolide)-b-methoxy-PEG (PLGA-PEG) nanoparticle prepared by 
nanoprecipitation (NPP) method is used as a negative control for comparing to the monodisperse 
silica NCs; [j] gram scale preparation of Cpt50* with 0.939 mL TEOS. 
 
Table 2.2 Reaction conditions of size-controlled Pyr-NC via Stöber method. 
 
 

















St-A 1.0 360 70 31.2
St-B 1.0 360 70 62.5
St-C 1.0 360 80 62.5
St-D 1.0 360 90 62.5
St-E 1.0 360 100 62.5
St-F 1.0 360 110 62.5
St-G 1.0 270 240 62.5
St-H 15.0 5400 1200 939











Trx-A cyclohexane 1.77 0 80 0 100%
Trx-B decane 1.77 0 80 0 100%
Trx-C cyclohexane 1.77 40 0 40 60.6%
Name of NC 
SEM [a] DLS [b]
D ± SD (nm) D ± SD (nm) PDI ± SD 
Pyr20 26.6 ± 2.7 43.8 ± 0.3 0.126 ± 0.030
Pyr50 43.4 ± 3.9 65.2 ± 0.4 0.110 ± 0.012
Pyr65 64.1 ± 3.1 88.5 ± 1.1 0.045 ± 0.022
Pyr80 84.4 ± 7.6 100.7 ± 0.8 0.028 ± 0.013
Pyr100 104.4 ± 8.8 129.3 ± 1.5 0.033 ± 0.018



































re 2.2 SEM 



















 nm or lar
ted, both 1


































 2.1a and 









EG90).   



























 = 39.2%, e
c sizes 
red to 
























































d dyes to 
n (Cpt), a 





















































 and cell m
ined uncha









d had the 









e of 20, 50































00 nm, the 




































EG via the 
EG5k-sil) 
ility in both













































































































































































ased in 48 
0 nM (dat
ine ester a




















in a much l
e ester is m
he ester bo






















e of silica N
ared bis-sila








































































fabrication methods are not only independent of agents, but are also independent of linker 
(e.g., in the context of using 3, entries 13-15, Table 2.1) or addition of other silane 
reagents (e.g., in the context of using degradable (8) or pH-sensitive (9) silane agent, 
entries 26-29, Table 2.1).  Study of the in vivo degradation and clearance of regular silica 








Figure 2.8 Tunable release profile and solid-form formulation of drug-silica nanoconjugates. a, 
Release kinetics of Cpt-NCs with different linkers between drug and NC and sizes in 50% human 
serum at 37°C. 
 
2.3.5. Stability of silica NCs 
Particle stability against aggregation in physiological conditions is a prerequisite for 
effective drug delivery in vivo. The Cpt-NCs synthesized for this study displayed 
remarkable stability in PBS (1×) at 37 °C, with NC size remaining essentially unchanged 
for 25 min (Figure 2.9). In order to prolong systemic circulation and reduce aggregation 
of NCs in blood,36 the surface of NCs was modified by 1-(2-(2-methoxyethoxy)ethyl)-3-
(3-(trimethoxysilyl)propyl)urea (PEG5k-sil; 10 in Scheme 2.1) to introduce surface-bound 
PEG groups (denoted as PEGylated; Scheme 2.1). PEGylated silica NCs were ~10 nm 
larger than the non-PEGylated NCs in hydrodynamic diameters (Figure 2.9a). When 
exposed to PBS (1×) for 4 h, non-PEGylated silica NCs showed signs of aggregation 

























(Figure 2.9b) while PEGylated silica NCs remained a single distribution under dynamic 
light scattering (DLS) because PEGylation imparted steric stability to silica NCs in salt 
solutions.   In addition to PEGylation, a variety of other surface properties—positively or 
negatively charged moieties, for example—can be realized using any of the large number 
of commercial silane coupling agents, thus demonstrating another advantage of our drug-
conjugated silica NCs.38  
 
Figure 2.9 Stability of PEGylated and Non-PEGylated silica NPs in PBS (1×).  
 
2.3.6. Gram scale formulation of Cpt-NCs 
Besides controlled particle size, drug loading and release kinetics, other issues critical to 
the clinical translation of NP drug delivery system, such as scalability, lyophilizability, 
and toxicity, should also be addressed. These issues may also present the bottleneck to 
the clinical translation of a nanomedicine. I found the silane chemistry could be easily 
used for the large-scale preparation of drug-containing NCs. I tested the preparation of 
one gram of 50-nm Cpt-NC in one pot, and successfully obtained NCs with the expected 
size (46.4  4.6 nm) in quantitative yield within one day (entry 25, Table 2.1; Figure 
2.10). The NP fabrication process that allows preparation of very small drug delivery NPs 
with remarkable control over size and monodispersity and with excellent scalability is 
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formulation of silica NCs with essentially no change of particle sizes after lyophilization 
and re-constitution in water (Figure 2.11).  
 




[a] In this study, silica NPs were was used to investigate the relationship between cyroprotectant 
and final NP sizes. The NPs were prepared via Stöber method. After NP formulation, various 
lyoprotectants were added and the mixture was subject for lyophilization. BSA: bovine serum 
albumin (from Fisher). No lyoprotectant was added for Entry 1 and 10. [a] Weight ratio of 
lyoprotectants to NPs. [b] Original hydrodynamic diameter in nm of the NP measured by DLS. [c] 
Hydrodynamic diameter in nm of the NP post lyophilization measured by DLS. [d] Ratio of NP 
diameters after lyophilization to original diameter. [e] The NPs aggregated (Y) or not (N) 
observed by eyes post lyophilization. 
 
2.4. Conclusions 
Silica NPs have been used in various drug and gene delivery applications.22, 23, 33, 39-59 For 
example, silica NPs with stably bound photosensitizer were used for photodynamic 
therapy;56 mesoporous silica NPs were explored extensively for the encapsulation and 
delivery of chemotherapeutics;45, 47, 48, 50-52, 57, 59-62 silica NPs were also used in gene 
delivery.46, 47, 58, 63 These studies set up the cornerstone for the continuous advancement 
Entry Lyoprotectant m(Lyo)/m(NP)[a] Do/nm[b] D/nm[c] D/Do[d] Aggr. (Y/N)[e]
1 None N/A 102.0 233.5 2.29 Y
2 Sodium chloride 10 102.0 2295.1 22.50 Y
3 BSA 1 102.0 139.1 1.36 N
4 BSA 5 102.0 120.6 1.18 N
5 BSA 10 102.0 142.0 1.39 N
7 Dextrose 1 102.0 108.1 1.06 N
8 Dextrose 5 102.0 101.5 1.00 N
9 Dextrose 10 102.0 99.5 0.98 N
10 None N/A 69.8 558.8 8.01 Y
11 Sodium chloride 10 69.8 2910.7 41.70 Y
12 BSA 1 69.8 103.6 1.48 N
13 BSA 5 69.8 91.0 1.30 N
14 BSA 10 69.8 97.8 1.40 N
15 Dextrose 1 69.8 84.3 1.21 N
16 Dextrose 5 69.8 68.9 0.99 N
17 Dextrose 10 69.8 71.2 1.02 N
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and novel design of silica NP based nanomedicine. In this chapter, I streamlined a 
process for developing potentially clinically applicable drug-silica nanoconjugate 
delivery system with well-controlled physicochemical and pharmacological properties. 
To the best of our knowledge, this is the only report of a drug/dye delivery nanomedicine 
platform that can be easily prepared in gram- or larger scale in dry powder form and can 
be controlled formulated to any desirable size ranging from 20 to 200 nm with 
monodisperse particle size distribution (CV < 10%). Due to formulation challenges, 
FDA-approved drug-delivery nanomedicines and others under clinical and preclinical 
investigations mostly have sizes over 100 nm. The silica NC provides a platform 
technology to make precisely size controlled nanoparticles with all the desired properties 
abovementioned for clinical drug delivery applications and fundamental studies.  
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CHAPTER 3  
SIZE EFFECT OF NANOMEDICINE ON THE PERFORMANCE OF 
OVERCOMING PHYSIOLOGICAL BARRIERS 
 
3.1. Introduction 
Nanomedicine, an emerging class of therapeutics for cancer, can improve drug efficacy 
while simultaneously reduce side effects because of properties such as more effective 
targeting to disease site than conventional chemotherapy.1-23 Although nanomedicine is a 
promising modality, facilitating its translation from the bench to the clinic has proven 
very difficult. Numerous studies have been performed to explore nanomedicine as a new 
modality for cancer treatment, but few have been performed clinically and even fewer 
have been approved for clinical applications.1 One possible reason is that the correlation 
between the physicochemical properties of nanomedicine and its biological performance 
is not fully understood.24 To address this issue, recent studies have examined this 
relationship on various aspects. For example, it was found that shape of polymeric 
micelles greatly impacts the blood circulation time.25 The surface charge of NPs also 
strongly affects the tissue penetration behavior.26 Increasing evidences showed that 
particle size plays a vital role in controlling systemic and lymphatic biodistribution, in 
vivo tumor targeting and penetration, and cellular trafficking of particulate drug delivery 
vehicles.1, 27-30, 2, 31, 24, 28, 32-41 NPs with size controlled within 20-60 nm have been 
particularly interesting and actively pursued because recent studies have showed that NPs 
within this size range have distinct biodistribution, tumor penetration and cellular 
trafficking properties that are critical to the in vivo use of nanomedicine. In Chapter 2, I 
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reported the development of novel drug conjugated silica NPs (Scheme 2.1, Chapter 2),44 
termed drug-silica nanoconjugates (drug-NCs), which can be formulated in a highly 
controlled manner at the desired sizes with very narrow size distributions. Because 
excellent size control is a prerequisite for studying the role of size of nanomedicine in 
biological performance, these monodisperse drug-NCs are ideal test subjects. Here I 
report the systematic comparison of drug-NCs of 20, 50 and 200 nm in diameter in 
cellular trafficking, cytotoxicity, biodistribution and tumor penetration and studies. It was 
founded that NCs ≤50 nm outperformed the larger NCs in cellular internalization, tumor 
accumulation and penetration. These results highlight the great promise for improving 
cancer therapy by controlling the size of nanomedicine ≤50 nm.  
 
3.2. Materials and Methods 
3.2.1. General 
Silica NCs were prepared as described in Chapter 2. The HeLa cells (ATCC, Manassas, 
VA, USA) used for MTT assays and cellular internalization studies were cultured in 
MEM medium containing 10% Fetal Bovine Serum (FBS), 100 units/mL aqueous 
Penicillin G and 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA, USA). The 
absorbance wavelength on a microplate reader (Perkin Elmer, Victor3TM V, Waltham, 
MA, USA) was set at 590 nm for MTT assay. Prior to use in tumor inoculation, EL4 or 
Lewis lung carcinoma (LLC) cells (ATCC) were cultured in DMEM medium containing 
10% FBS, 100 units/mL aqueous Penicillin G and 100 μg/mL streptomycin. The confocal 
microscopy images for cell internalization studies were taken on a Zeiss LSM700 
Confocal Microscope (Carl Zeiss, Thornwood, NY, USA) using a 63×/1.4 oil lens with 
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excitation wavelength set at 405 nm and 555 nm. The flow cytometry analysis of cells 
was conducted with a BD FACSCanto 6 color flow cytometry analyzer (BD, Franklin 
Lakes, NJ, USA). For the ex vivo study, the flash frozen tumor tissue embedded with 
optimum cutting temperature (O.C.T.) compound (Sakura Finetek, USA) was sectioned 
(20 µm thick) with a Leica CM3050S cryostat and mounted on glass slides. The tissue 
sections were observed on a fluorescence microscope (Zeiss Axiovert 200M) with 
excitation wavelength at 780 nm. For the in vivo study, the formalin-fixed, paraffin-
embedded tumor sections measuring 5 µm in thickness were prepared by the Veterinary 
Diagnostic Laboratory histopathology service at University of Illinois at Urbana-
Champaign (Urbana, IL, USA). The tissue sections were analyzed under Zeiss LSM700 
confocal microscope for in vivo tumor penetration study. For biodistribution studies, the 
organs were fixed in 10% formalin; the fluorescence of the whole organ was measure ex 
vivo at emission wavelength of 800 nm using Odyssey infrared mouse imaging system 
(LI-COR, Lincoln, NE, USA). C57BL/6 mice (female) and Balb/c nude mice (male) were 
purchased from Charles River Laboratories (Wilmington, MA, USA). Feed and water 
were available ad libitum. The study protocol was reviewed and approved by the Animal 
Care and Use Committee (IACUC) of University of Illinois at Urbana Champaign. For 
both ex vivo and in vivo studies, C57BL/6 mice were injected subcutaneously in the right 
flank with 1 × 106 LLC cells  or EL4 cells suspended in a 1:1 mixture of Hank's Balanced 
Salt (HBS) buffer and matrigel (BD Biosciences, Franklin Lakes, NJ, USA).  
 
3.2.2. Cellular internalization of RITC-NCs 
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Qualitative analysis by confocal laser scanning microscopy. The HeLa cells were used to 
investigate the uptake of RITC20, RITC50 and RITC200 (Table 2.1). HeLa cells (50,000) 
were seeded in a 4-well chamber slide for 24 h (37 °C, 5% CO2). Cells were washed once 
with opti-MEM and then incubated for 1 h (37 °C) with opti-MEM (1 mL) containing 
100 µg/mL corresponding RITC-NCs. The cells were then washed by PBS (1 mL) for 
three times, fixed with 4% paraformaldehyde and subsequently imaged on a confocal 
laser scanning microscope. Nuclei were stained by 4',6-diamidino-2-phenylindole (DAPI). 
Cells without the addition of RITC-NCs were imaged as the control.  
 
Quantitative analysis by flow cytometry. HeLa cells (1 × 105) were seeded in a 12-well 
plate for 24 h. RITC-NCs (100 µg/mL) were incubated with the cells in opti-MEM (1 mL) 
over a time course ranging from 30 min to 90 min (37 °C). The cells were then washed 
with PBS (3 × 1 mL) and detached via trypsinization. Cells were fixed with 4% 
paraformaldehyde for flow cytometry analysis (1 × 104 cells analyzed, red fluorescence, 
PE channel). Both the percentage of the fluorescent cells relative to the total analyzed 
cells and the fluorescence intensity of the fluorescence-positive cells were assessed. All 
experiments were performed in triplicate. 
 
Quantitative analysis by microplate reader. HeLa cells were seeded in 24-well plates at a 
density of 5×104 cells/well and cultured for 24 h. After that, the culture medium was 
replaced by opti-MEM and pre-incubated at 37 °C for 30 min followed by addition of 
RITC-labeled NCs of 50 or 200 nm at 100 μg/mL. After incubation at 37 °C for 2 h, the 
medium was discarded, and cells were rinsed with PBS (1×) for three times. The cells 
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were then lysed with 500 μL/well of 0.5% SDS (pH 8.0) at room temperature for 20 min. 
Content of RITC-labeled NCs in the lysate was quantified by microplate reader (ex 570 
nm, em 590 nm). Protein content was measured using the Pierce BCA protein assay 
(Rockford, IL). A standard curve was obtained using a bovine serum albumin (BSA) 
solution. Uptake level was expressed as percentage of the total fluorescence present in the 
feed solution normalized by mg of protein (Figure 3.2).  
 
Mechanism study of cellular internalization process. To explore the mechanism involved 
in the uptake process, cells were incubated with either the metabolic inhibitor sodium 
azide (0.1%) and 2-deoxyglucose (50 mM), the clathrin inhibitor chlorpromazine (10 
μg/mL), the caveolar inhibitor genistein (0.2 mM) or methyl-β-cyclodextrin (m-βCD) 
(5.0 mM), or wortmannin (10 μg/mL) for 30 min prior to the addition of RITC-labeled 
NCs and throughout the 2 h uptake experiment at 37 °C. Results were expressed as the 
percentage of the total fluorescence present in treated cells relative to untreated cells 
according to the quantitative procedure described above. 
 
3.2.3. Cytotoxicity of Cpt-NCs by MTT assay. 
HeLa cells were seeded in 96-well plates at 3,000 cells/well and grown in MEM medium 
containing 10% FBS at 37°C for 24 h in a humidified 5% CO2 atmosphere. The medium 
was replaced with fresh medium containing Cpt, Cpt-NCs or blank silica NCs in 
concentrations ranging from 1 nM to 10 µM of Cpt or equivalent Cpt. At each 
concentration of six wells per plate were treated. The cell viability was determined by the 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay after 72 h. 
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The standard MTT assay protocols were followed thereafter.45 The IC50’s of various drug-
NCs were listed in the Table 3.1. Cytotoxicity of Cpt-NCs to LnCaP and PC3 cells was 
measured similarly.  
 
3.2.4. Ex vivo tumor penetration study 
C57BL/6 mice (female, 12-13 week old) bearing LLC tumors were sacrificed to collect 
the tumors when the tumors grew to ~ 7.0 × 8.0 mm. Tumors (n = 3) were ex vivo 
cultured with IR20, IR50 or IR200 (Table 1) at concentration of 3 mg/mL NC in cell 
medium for 48 h. Tumor without any treatment served as the control. Tumor sections (20 
µm thickness) were collected by cryostat and mounted on glass slides. Fluorescent 
images were taken on a Zeiss Axiovert 200M fluorescence microscope with 780 nm laser 
excitation. A tiling image was taken with fixed exposure time to show the NC penetration 
in tumor sections. The fluorescence intensity in tumor sections was analysed by Image J. 
To quantify the penetration of NCs, I defined the tumor tissue penetration depth as the 
distance from the periphery of the tumor to the site where the fluorescence intensity 
decreased by 95% as compared to the fluorescent intensity at the tumor periphery.  
 
12-13 week old, female C57BL/6 mice were injected subcutaneously on the right flank 
with 10×106 EL4 cells suspended in a 1:1 mixture of HBS buffer and matrigel. When the 
EL4 tumor size reached ~6.0-8.0 mm, the mice were sacrificed and their tumors 
harvested. Tumors were cultured ex vivo in cell media with IR783-labeled NCs of 50 or 
200 nm for 48 h. Tumors without any treatment served as control. Tumor sections (20 µm 
thick) were collected by cryostat and mounted on glass slides. Fluorescence images were 
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taken by fluorescence microscopy (λex=780 nm). A tiling image was taken with fixed 
exposure time to show part of the edge and inside area of tumor sections. The 
fluorescence profile from the tumor surface to the inside was analyzed by Image J.  
 
3.2.5. In vivo tumor penetration study 
LLC tumor-bearing C57BL/6 mice were divided randomly into groups of three (n = 3) 
and were treated when the mean tumor diameter was in the range of 5.0~6.0 mm. Each 
animal received a PBS solution of RITC20, RITC50 or RITC200 (200 L, 50 mg/mL) 
through tail vein administration. The animals were euthanized 24 hours after 
administration. The tumors were collected, fixed by 10% formalin, and then embedded in 
paraffin prior for tissue sectioning and immunohistochemical staining. A tissue section 
with approximate thickness of 5 µm were collected from each tumor, mounted on glass 
slides, and allowed to air-dry. Fluorescence images were taken on a Zeiss LSM 700 
confocal microscope. Tissue sections were imaged with a 10×/0.3 lens. Developing tumor 
neovasculature within each tumor section was identified by the expression of Von 
Willebrand Factor (Factor VIII-related antigen) by incubating slides with a rabbit 
polyclonal anti-human Factor VIII antibody (1:200) for 30 minutes at room temperature. 
Following primary antibody incubation, glass slides were stained with a FITC-conjugated 
goat polyclonal anti-rabbit antibody (1/250) for 4 hours in the dark, then coverslipped 
using VECTASHIELD mounting media (Burlingame, CA). FITC fluorescence 
representing endothelial cells was visualized using 488 nm laser excitation. Red 





IR783-labeled NCs of 50 or 200 nm were intravenously (i.v.) administered to C57BL/6 
mice (n=3) bearing EL4 tumors (size: ~6.0-8.0 mm) at a dose of 150 mg/kg. Mice were 
euthanized 24 hours post-injection and their tumors were collected. Tumor sections with 
2 mm thickness were collected and placed on glass slides. Fluorescent images were taken 
with Odyssey infrared imaging system at an 800 nm emission wavelength. Histograms of 
the fluorescent intensity of selected areas (indicated by the lines) in the fluorescence 
images of tumor sections (Figure 3.7a) were analyzed by Image J (Figure 3.7b).  
 
3.2.6. In vivo biodistribution study  
C57BL/6 mice bearing LLC tumors (~5.0 × 6.0 mm) (n=3) were divided into three 
groups, minimizing tumor size variations between groups. Mice were injected 
intravenously with IR20, IR50 and IR200 at a dose of 150 mg/kg. Mice were euthanized 
and dissected 24 hours post injection. The major organs (liver, spleen, kidney, heard, 
bladder, lung and tumor) were collected and fixed in 10% formalin. The fluorescent 
intensity of IR-NCs in each organ was measured ex vivo at 800 nm emission using 
Odyssey infrared mouse imaging system (LI-COR, Lincoln, NE, USA). The 
concentration of the IR-NCs in each organ was determined by comparing its fluorescent 
intensity against a standard curve of IR-NCs.  
 
BALB/c nude mice (8-week old) were injected subcutaneously on the right flank with 
4×106 LNCaP cells suspended in a 1:1 mixture of HBS buffer and matrigel. When the 
tumor grew to ~12 mm, mice bearing LnCaP tumors were divided into groups of two so 
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as to minimize tumor size variations between groups. Mice were injected intravenously 
with IR783-labeled NCs of 50 or 200 nm at a dose of 150 mg/kg. Mice were euthanized 
24 hours post-injection and fixed in 10% formalin. Whole body images were taken with 
the Odyssey infrared imaging system (λem=800 nm). Mouse organs, including the tumor, 
liver, spleen and kidneys were harvested. The fluorescence of each tissue was assayed 
with the Odyssey infrared imaging system directly. The measurements of the various 
organs were validated using a phantom of free IR783 solution on top of tissues of various 
thicknesses. All organs used for fluorescence measurement were no thicker than 2 mm 
with >80% transmission 44. To determine 100% dose, a diluted solution of IR783-labeled 
NCs was measured along with tissues at the same instrument settings. The data is 
presented as percent injected dose per gram of tissue (average ± standard deviation).  
 
3.2.7. Statistical analyses 
Student T-Test (two tailed) comparisons at 95% confidence interval were used for 
statistical analysis. The results were deemed significant at 0.01 < p  0.05, highly 
significant at 0.001 < p  0.01, and extremely significant at p  0.001.  
 
3.3. Results and Discussion 
3.3.1. Size effect on cellular internalization and trafficking 
As I prepared drug(dye)-NCs with precisely controlled size, I next use this new drug 
delivery system to study the size effect of on their cellular internalization, in vivo 
biodistribution and tumor tissue penetration. All silica NCs involved in the following in 
vitro and in vivo studies have identical surface properties, spherical shape and chemical 
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structures and compositions; particle size was the only parameter changed in these studies. 
Pegylated silica NCs with discrete sizes of 20, 50 and 200 nm containing rhodamine B 
(RITC) (termed RITC20, RITC50 and RITC200, respectively) were prepared at a 4:6 
ratio of 10 (entries 19-21, Table 2.1; Figure 2.4). To facilitate in vivo/ex vivo analysis of 
fluorescent NCs with reduced autofluorescence, I prepared pegylated NCs containing 
IR783, a near inferred (NIR) dye at a 5:6 ratio of 10; the resulting NIR active NCs with 
discrete sizes of 20, 50 and 200 nm were denoted as IR20, IR50 and IR200, respectively 
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While the NCs diffuse into tumor tissue, whether the NCs stay in interstitial extracellular 
matrix or are internalized and reside inside the cells should impact the penetration depth 
in tumor tissue as well as the capability of retention. I thus compared the size-dependent 
uptake of these NCs in HeLa cells. Cellular internalization of RITC20, RITC50 or 
RITC200 into the HeLa cells for 30, 60, or 90 minute incubation was analyzed by 
fluorescence-assisted flow cytometry (FACS) to assess the kinetics of NC internalization 
(Figure 3.1a). I found that smaller NCs were internalized into HeLa cells faster and more 
efficiently than NCs with larger size, in terms of both percentage of the fluorescent cells 
and total accumulated mean fluorescence intensity. The number of fluorescent cells 
accounts for 1.4%, 6.6% and 9.2% of the total treated cells for 30-, 60- and 90-minute 
incubation with RITC200. These numbers were 6.6%, 37.2% and 55.2% for RITC50, and 
21.9%, 49.1% and 71.0% for RITC20, respectively (Figure 3.1a). The fluorescence 
intensities of cells for 30-, 60- and 90-minute incubation with RITC200 were 0.18, 0.25 
and 0.28, in arbitrary units of FACS. These numbers were 0.23, 1.15 and 1.52 for 
RITC50 and 0.73, 1.99 and 5.25 for RITC20, respectively (Figure 3.1b). The 20-nm NC 
was therefore internalized 18.7 times and 3.5 times more than 200-nm and 50-nm NC for 
a total of 90-minute incubation. Interestingly, comparing the fluorescence intensity 
change of the three 30-minute blocks (0-30 min, 30-60 min and 60-90 min), I found the 
rate of internalization of 20-nm NC (RITC20) in HeLa cells were accelerating in the first 
90 minutes while the accumulation of 200-nm NC (RITC200) were evidently de-
accelerating (Figure 3.1c). For RITC200, 90-minute incubation versus 30-minute 
incubation resulted in an increase of the number of the fluorescent cells by 660% (9.2% 
vs. 1.4%), but the total accumulated fluorescence intensity was only increased by 56% 
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(0.28 vs. 0.18), suggesting that not all internalized RITC200 can be effectively retained 
inside of the cells and exocytosis might occur simultaneously.46 In contrast, 90-minute 
incubation versus 30-minute incubation of RITC20 resulted in an increase of the number 
of fluorescence cells by 340% (71% vs. 21%) and the total accumulated fluorescence 
intensity by 720% (5.25 vs. 0.73), clearly indicating that 20-nm particle can be effectively 
internalized and retained in the cells, and the internalization/retention process become 
more favorable for the duration of study. The size-dependent cell-uptake and retention 
was also verified by confocal microscopy study (Figure 3.1d), which demonstrated that 
NCs with smaller sizes were internalized and retained inside the cells more efficiently 
than the NCs with larger sizes.  
 
I also compared RITC50 and RITC200 in cellular trafficking studies. Similarly, the 
confocal laser scanning microscopy images obtained (Figure 3.2a) clearly showed a 
stronger fluorescent signal in HeLa cells incubated with RITC50 as compared to 
RITC200, suggesting that the smaller NCs were internalized more efficiently than their 
larger counterparts. The relative levels of internalization were further quantified using a 
microplate reader to measure the percentage of the total fluorescent signal internalized by 
cells normalized to the amount of total cell protein. As expected, 50 nm NCs showed a 3-
fold increased cellular internalization efficiency as compared to 200 nm NCs (9.60 and 
3.23 %/mg for NCs of 50 and 200 nm respectively, Figure 3.2b). It is noticeable that, 50 
nm NCs administered to HeLa cells accumulated in the perinuclear region while the 
majority of 200 nm NCs resided on or near the cell surface (Figure 3.2a). This 
observation suggests that, in addition to the amount of uptake, NC size might also 
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influence the uptake pathway. In order to probe the mechanism of cellular internalization, 
I investigated the uptake in HeLa cells in the presence of various biochemical inhibitors 
of known internalization pathways (Figure 3.2c). Toxicity due to the inhibitors was 
negligible (Figure S3). When HeLa cells were pre-incubated with NaN3/2-deoxyglucose 
(NaN3/DOG)—an inhibitor of cellular adenosine-5'-triphosphate (ATP) synthesis and 
thus active/energy-dependent endocytosis—for 30 min before adding silica NCs, the 
cellular internalization for both 50 and 200 nm NCs was significantly decreased (73.5% 
and 67.6%, respectively) compared to untreated cells. As the internalization of both NCs 
was not completely inhibited, it is likely that a small portion of the NCs can be 
internalized through a non-energy dependent processes or that exogenous ATP existed in 
the cell medium.28 When the cells were pre-treated with chlorpromazine, an inhibitor of 
clathrin-mediated endocytosis, or wortmannin, an inhibitor of macropinocytosis, a 
significant decrease in internalization was observed for 200 nm NCs (40.2% and 57.0%, 
respectively) but not for 50 nm NCs. However, when the cells were pre-treated with 
genistein or methyl-β-cyclodextrin (m-βCD)—both inhibitors of caveolae-mediated 
uptake—only the internalization of 50 nm NCs was significantly decreased (62.2% and 
70.0%, respectively). These results indicated that caveolae-mediated endocytosis played 
an important role in the internalization of the smaller 50 nm NCs while clathrin and 
macropinocytosis were the major pathways for 200 nm NCs. Existing literature indicates 
that caveolar invaginations have diameters of approximately 50-80 nm and can 
accommodate cell entry of NPs up to 100 nm.47-49 Thus, it is not entirely surprising that 
50 nm NCs and not 200 nm NCs enter cells through caveolae-mediated pathways. The 
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(Table 3.1 cont.)  [a] IC50’s of Cpt20, Cpt50 and Cpt 200 (prepared using 5) to LnCaP prostate 
adenocarcinoma cells determined by MTT assay. Cells were cultured with the treatment for 96 h. 
[b] IC50’s of Cpt-N20, Cpt-N50 and Cpt-N200 (prepared using 6) to HeLa cells determined by 
MTT assay. Cells were cultured with the treatment for 72 h. 
 
3.3.2. Size effect on cytotoxicity 
The overall cytotoxicity of Cpt-NCs was evaluated and compared with free Cpt using a 
MTT assay. The resultant IC50 values for Cpt20, Cpt50 and Cpt200 in LNCaP cells were 
220, 510 and 800 nM, respectively (Table 3.1). The cytotoxicity of the Cpt-NCs 
corresponded to the cellular internalization as well as the amount of Cpt released by the 
NCs—the Cpt20, Cpt50 showed higher toxicity to cancer cells and a lower IC50 value as 
compared to the Cpt200presumably because the smaller particles experienced more rapid 
cellular internalization and faster Cpt release. The cytotoxicity of Cpt-N20, Cpt-N50 and 
Cpt-N200 with much faster release profiles was evaluated in HeLa cells, resulting in a 
much lower IC50 value (9.0, 17 and 22 nM for Cpt-N20, Cpt-N50 and Cpt-N200 
respectively, Table 3.1). In human serum, Cpt20 with the hydrophobic thioether ester 
linker between Cpt and the silica particles showed sustained drug release with 14.8% of 
CPT being released in 48 hours (Figure 2.8); the IC50 value of Cpt20 in LNCaP cells was 
found to be 220 nM. When the linker was changed to a hydrophilic amine ester as in Cpt-
N20 (entry 13, Table 2.1; Figure 2.1), which was prepared by using 6 as the 
corresponding drug-containing silane reagent (Scheme 2.1), the Cpt release kinetics can 
be dramatically accelerated with Cpt being 100% released within 48 hours, resulting in a 
much lower IC50 value. This could be due to the fact that hydrophilic amine ester is more 
assessable by water and esterase which can accelerate the cleavage of the ester bond. By 
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(Figure 3.3 cont.) study. (i) A phantom with known concentration of IR783 was first measured to 
give the number f; (ii) then the same  phantom was put on top of a tissue of certain thickness, the 
FL was measured again to give f’. An example of the validation experiment with 2-mm thick 
liver tissue was shown with the images obtained. c, Percent transmission of various mouse tissues 
with different thickness was calculated as: Transmission=f’/f × 100%. 
 
3.3.3. Size effect on biodistribution 
IR783 (IR), a near infrared dye with excitation wavelength of 779-785 nm, was used in 
the biodistribution study in order to minimize the autofluorescence for the tissues for the 
quantification IR-NCs. To verify the quantitative measurement of the fluorescence 
intensity in tissues, I performed a serial of calibration studies (Figure 3.3). For each organ, 
the background fluorescence (FL) of a control tissue was subtracted from the FL of the 
tissue from the treated mice. As the thickness of the tissues has significant effect on the 
accuracy of the FL measurement, I designed an experiment to determine the maximum 
thickness of the tissues that allows 100% recovery of the FL activity (Figure 3.3b). I first 
measured the FL activity of the IR783 placed in a phantom and the FL intensity was 
denoted as f. Next, I placed a tissue (as shown in (ii)) on the scanner and then put the 
same IR783-containing phantom on top of the tissue. The measured FL intensity was 
denoted at f’. The ratio of f’/f (see Figure 3.3c) is the FL recovery efficiency (i.e., FL 
penetration efficiency). As shown in Figure 3.3c, only 10-25% of FL was recovered for 
FL allowed to penetrate a 6-mm thick tissue. However, when the tissue thickness is 2 mm 
or less, the FL recovery efficiency is essentially quantitative. I thus measured the FL 




In the biodistribution study of IR20, IR50 or IR200 in vivo using C57BL/6 mice bearing 
subcutaneously implanted Lewis lung carcinoma (LLC), tail vein intravenous (i.v.) 
administration of the NCs followed by tissue harvesting 24-hour later showed that 
majority of NCs were accumulated in liver and spleen, few were in the respiratory and 
urinary systems (Figure 3.4). The fluorescence of IR was found to have excellent tissue 
transmission; IR concentration can be quantitatively assessed in tissues with thickness 2 
mm or less (Figure 3.3). Importantly, NCs with smaller sizes distributed and accumulated 
in the tumor tissue more efficiently than NCs of larger sizes (Figure 3.4). The injected 
doses of NCs normalized for tumor tissue weight (I.D.%/g) were 4.18  0.81, 0.98  0.59 
and 0.52  0.05 for IR20, IR50 and IR200, respectively. A decrease in particle size by 
2.5-fold from 50 nm to 20 nm resulted in an increase of NC concentration by 330% in 
tumor tissue (from 0.98 to 4.18, **p < 0.01). In comparison, a decrease in particle size by 
4-fold from 200 nm to 50 nm resulted in an increase of NC concentration in tumor tissue 
by only 88% (from 0.52 to 0.98). NC size showed significant influence on the systemic 
and tissue biodistribution, and this effect seems to be more profound for NCs below 50 
nm in size. These results underscore the importance of studying nanomedicines with sizes 
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(Figure 3.4 cont.) fidelity of utilizing Odyssey infrared imaging system for quantitative IR 
analysis in biological tissues was verified in a series of control studies (Supplementary Figure S6). 
All the organ distribution are presented as percentage of injected dose (I.D.%, a).Tumor 
accumulation data are presented as percentage of injected dose per gram of tumor tissue (I.D.% / 
g tissue, b). Student’s t-test (two-tailed) was performed for statistical analysis: n.s., not significant; 
highly statistical significant with 99% confidence, **p < 0.01. c), d) LLC tumors (size: ~7.0 mm 
× 8.0 mm, n = 3) were ex vivo cultured with IR20, IR50 or IR200 in cell culture medium for 48 h. 
The tumors without any treatment served as the control. The tumor sections of treatment groups 
(intersections, 20 µm in thickness) were collected by cryostat, mounted on glass slides and 
analyzed on a fluorescence microscope at (excitation = 780 nm). A tiling image was taken with 
fixed exposure time to show the NC penetration in tumor sections. Scale bar = 500 µm. The 
fluorescence profile in tumor section was analyzed by Image J (c) to show the depth of NC 
penetration in tumor tissues. To quantify the penetration, I defined the tumor tissue penetration 
depth as the distance from the periphery of the tumor to the site where the fluorescence intensity 
decreases by 95% as compared to the fluorescent intensity at tumor periphery. The penetration 
depths of IR20, IR50 and IR200 were found to be 1396 µm, 660 µm and 88 µm, respectively. e) 
C57BL/6 mice bearing LLC tumors (size: ~5.0 mm × 6.0 mm, n = 3) were injected intravenously 
with RITC20, RITC50 or RITC200. Mice were euthanized and dissected 24 hours post injection. 
Tumor sections (intersections, 5 µm in thickness) were collected in paraffin and mounted on glass 
slides. Fluorescence images were taken on a Zeiss LSM 700 confocal microscope. Representative 
two-color composite images showing the perivascular distribution of RITC-NCs (red, Rhd 
channel) relative to the blood vessels (green, FITC channel) in tissue sections of LLC tumors 
were showed and overlaid. Scale bar = 100 µm. 
 
Similarly, IR50 and IR200 were also compared for their performance in in vivo 
biodistribution studies using another tumor model, e.g. LNCaP xenograft human prostate 
cancer model in mice. The near infrared dye labeled silica NCs were i.v. administered to 
Balb/c nude mice bearing LNCaP tumors and whole body image scans were performed 
on an Odyssey infrared imaging system 24 h post-injection at em=800 nm with fixed 
exposure time (Figure 3.5a, tumors indicated by black circles). Enhanced fluorescence 
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vasculature should have significant effect on the retention of NCs. I went on and studied 
the size dependency of silica NCs diffusion/penetration in tumor tissues. I performed the 
tumor penetration study by incubating LLC tumors (grown in C57BL/6 mice with ~200 
mg) for 48 hours in culture medium containing equal concentration of IR20, IR50 or 
IR200. The tumor sections (20 µm in thickness) were then analyzed by NIR fluorescence 
microscope. As shown in Figure 3.4c the size dependency of tumor penetration was 
obvious with IR20 penetrating tumor tissue with the greatest depth from the periphery of 
the tumors, followed by IR50 with intermediate penetration depth and IR200 with limited 
tumor penetration. To quantify the penetration, I defined the tumor tissue penetration 
depth as the distance from the periphery of the tumor to the site where the fluorescence 
intensity decreases by 95% as compared to the tumor periphery fluorescent intensity. The 
penetration depths of IR20, IR50 and IR200 were found to be 1,396 µm, 660 µm and 88 
µm, respectively (Figure 3.4d). The penetration depth of IR20 is twice and sixteen times 
of that of IR50 and IR200, respectively. To verify the size-dependency of tumor 
penetration in vivo, I intravenously administered RITC20, RITC50 and RITC200 to LLC-
bearing C57BL/6 mice via tail vein. Tumors were collected 24 hours post-injection, fixed 
and sectioned. After the blood vessel was stained with human Von Willebrand Factor 
antibody (green, FITC channel in Figure 3.4e), the tumor tissues were then analyzed 
using confocal microscope to study the distribution of NCs in tumor tissues relative to the 
blood vessels. This study showed the effect of biodistribution and diffusion collectively. 
RITC20 and RITC50 significantly outperformed RITC200, and diffused away from and 
situated distally to the blood vessel. Comparing the representative regions of interest, the 
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(Figure 3.8 cont.) was taken with fixed exposure time to show part of edge and center of tumor 
sections. Scale bar: 500 µm. d, Fluorescence profile from the tumor surface to the inside was 
analyzed by Image J. 
 
To more quantitatively evaluate the passive diffusion of silica NCs into tumor tissues, I 
performed an ex vivo tumor penetration study by culturing EL4 tumors harvested from 
tumor-bearing mice and exposing them to IR50 and IR200 for 48 hours. After incubation, 
tumor sections of 20 µm thickness were analyzed by fluorescence microscopy at ex=780 
nm with fixed exposure time (Figure 3.8a-c). Generally, the 50 nm NCs penetrated 
deeper into the solid tumor with overall higher internal fluorescence intensity than 200 
nm NCs. The 200 nm NCs, by comparison, were almost completely localized to the 
surface of tumors. To quantitatively compare the penetration depth of these different size 
NCs, the plot profile of fluorescence intensity versus distance from tumor edge to center 
was generated by Image J (Figure 3.8d). Penetration depth was defined as the depth at 
which fluorescence intensity drops to <5% of the maximum intensity at the tumor edge. 
According to this definition, 50 nm NCs were able to penetrate tumor tissue as deep as 
656 µm whereas 200 nm NCs reached a penetration depth of only 152 µm. Collectively, 
both our ex vivo and in vivo studies revealed that 50 nm NCs could penetrate tumor tissue 
more efficiently, likely because the smaller 50 nm NCs had better vascular permeation 
capability and could diffuse more efficiently into tumor interstitial space. Thus, similar 
trend was observed in EL4 tumor models. 
 
The distribution of many anticancer drugs and nanomedicines in tumor tissues is 
incomplete due to the large distance between blood vessels in solid tumors, the 
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composition of the extracellular matrix, cell-cell adhesion, high interstitial fluid pressure 
and lack of convection.57 As such, poor tumor penetration of anticancer drugs is a 
limiting factor in chemotherapy efficacy.58 Very recently, substantial effort has been 
dedicated to improving the tumor penetration of drugs.26, 59 Studies have indicated that 
penetration of NPs into the core of spheroids used as an in vitro tumor model is limited to 
particles smaller than 100 nm.60 Furthermore, Chan and colleagues reported that 20- and 
60-nm gold NPs permeated tumor tissues much more rapidly than 100 nm particles in 
vivo 27. Based on these findings, it is reasonable to expect that Cpt50, with small and 
monodisperse size, may show enhanced solid tumor penetration than larger drug delivery 
vehicles, thereby potentially exhibiting improved therapeutic efficacy.  
 
3.4. Conclusions 
In Chapter 2, I streamlined a process for developing potentially clinically applicable 
drug-silica nanoconjugate delivery system with well-controlled physicochemical and 
pharmacological properties. In this study, I formulated silica NCs with excellent size 
control to study the impact of size of nanomedicine on different biological barriers. NCs 
with size ≤50 nm were demonstrated to outperform their larger counterparts in terms of 
cellular internalization, in vivo tumor targeting and penetration. These results strongly 
emphasize the importance of controlling the size of nanomedicine ≤50 nm to achieve 
enhanced efficacy. Using the novel drug-silica chemistry described in this article, I can 
easily prepare monodisperse drug-NCs ≤50 nm with excellently controlled size. This 
formulation strategy holds great potential for further improvement in cancer treatment via 
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CHAPTER 4  
SIZE EFFECT OF NANOMEDICINE ON THE ANTICANCER EFFICACY 
 
4.1. Introduction 
Nanomedicines, an emerging class of therapeutics for cancer, can improve drug efficacy 
and simultaneously reduce side effects because they can more effectively target disease 
site than conventional chemotherapeutics.1-23 Increasing evidences indicate that particle 
size plays a vital role in controlling systemic and lymphatic biodistribution, in vivo tumor 
targeting and penetration, and cellular trafficking of particulate drug delivery vehicles.1, 
24-27 As more data highlight the importance of controlling the size of nanomedicines, it is 
crucial to study and understand the size effect of nanomedicine on anticancer efficacy in 
order to develop optimized drug formulations. Many nanomedicines, including FDA-
approved Doxil and Abraxane, are in the size range of ~100-200 nm.28, 29 These 
nanomedicines showed limited accumulation and penetration in hypovascular tumors.30, 
31 Some recent studies from our group32, 33 and other groups24, 34 demonstrated the benefit 
of controlling the particle size of nanomedicine ≤50 nm for improved accumulation and 
penetration in tumors, suggesting the importance of synthesizing and studying 
nanomedicines ≤50 nm. However, the correlation between the size of nanomedicines and 
their overall antitumor efficacy has not been fully studied and understood. I described the 
development of the novel drug conjugated silica NPs in Chapter 2 (Scheme 2.1),33 termed 
drug-silica nanoconjugates (drug-NCs), which can be formulated in a highly controlled 
manner at the desired sizes with very narrow size distributions. Because excellent size 
control is a prerequisite for studying the role of size of nanomedicine in biological 
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performance, these monodisperse drug-NCs are ideal test subjects in size dependent 
efficacy studies. I have shown that 50-nm and 20-nm NCs were superior to 200-nm NCs 
in tumor tissue accumulation and penetration in a subcutaneous murine Lewis Lung 
Carcinoma model (Chapter 3). Here I report the systematic comparison of camptothecin-
silica nanoconjugates (Cpt-NCs) of 200, 50 and 20 nm diameters in in vivo efficacy 
studies with different tumor models including both primary and metastatic tumor models. 
I find that Cpt-NCs of 50 nm outperforms the NCs of other sizes not only in inhibition of 
primary tumor growth but also the prevention of tumor metastasis. These results highlight 
the great promise for improving cancer therapy by controlling the size of nanomedicine 
≤50 nm.  
 
4.2. Materials and Methods 
4.2.1. General 
All silica nanoconjugates (NCs) used here were prepared as described in Chapter 2. 
Matrigel™ matrix and Biocoat™ Matrigel™ invasion chambers were obtained from BD 
Biosciences (Bedford, MA). D-luciferin potassium was obtained from Regis 
Technologies (Morton Grove, IL). The AIN-93G semi-purified diet was purchased from 
Research Diets (Brunswick, NJ). The MCF-7 cells (ATCC, Manassas, VA) were cultured 
in DMEM medium containing 10% Fetal Bovine Serum (FBS) and supplemented with 
100 units/mL aqueous Penicillin G, 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA).  
For the culture of MCF-7 cells, 1 nM estrogen (Sigma-Aldrich Inc., St. Louis, MO) was 
added to the cell media. The absorbance wavelength on a microplate reader (Perkin 
Elmer, Victor3TM V, Waltham, MA, USA) was set at 570 nm for MTT assay. The 
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confocal microscopy images for cell internalization studies were taken on a Zeiss 
LSM700 Confocal Microscope (Carl Zeiss, Thornwood, NY, USA) using a 63×/1.4 oil 
lens with excitation wavelength set at 405 nm and 555 nm. Murine 4T1 cells engineered 
with firefly luciferase were provided by Dr. David Piwnica-Worms from Washington 
University (St. Louis, MO). Dulbecco’s Modified Eagle’s Medium (DMEM) was 
obtained from the Cell Media Facility, University of Illinois at Urbana-Champaign 
(Urbana, IL). Heat-inactivated Fetal Bovine Serum (HI-FBS) was purchased from Atlanta 
Biological (Lawrenceville, VA). Penicillin/streptomycin and trypsin/EDTA were 
purchased from Invitrogen (Carlsbad, CA). 4T1 cells were maintained in DMEM 
supplemented with 10% HI-FBS, 100 unit/mL penicillin and 100 µg/mL streptomycin at 
37oC in a humidified incubator filled with 5% CO2. Cells were harvested at 70% 
confluence, counted and re-suspended in sterile PBS for injection. Female C57BL/6 mice 
were purchased from Charles River, USA. Female athymic nude mice were purchased 
from the National Cancer Institute (NCI, Frederick, MD) and ovariectomized at the age 
of 21 days by the vendor. After arrival, mice were single-cage housed and had free access 
to food and water. Female Balb/c mice were purchased from NCI at 4-week old of age 
and were accommodated for one week upon arriving. Feed and water were available ad 
libitum. Animals were maintained under animal protocols approved by The Illinois 
Institutional Animal Care and Use Committee (IACUC) of University of Illinois at 
Urbana Champaign. Micro-PET/CT imaging was performed with small animal dedicated 
Siemens Inveon PET-CT system (Siemens Healthcare, USA). Ex vivo measurement of 
the radio activity was conducted with 2480 Wizard2 Automatic Gamma Counter (Perkin-
Elmer, USA). Bioluminescence imaging (BLI) was performed using a custom made 
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imaging system (Stanford Photonics, Palo Alto, CA) with a dual micro-channel plate 
ICCD camera. 
 
4.2.2. Cellular internalization of silica NPs with different sizes. 
Qualitative analysis by confocal laser scanning microscopy. The MCF-7 cell line was 
used to investigate the cellular uptake of RITC-NCs of various sizes. MCF-7 cells 
(50,000) were seeded in a 4-well chamber slide for 24 h. Cells were washed once with 
opti-MEM. Cells were then incubated for 1 h at 37°C with opti-MEM (1 mL) containing 
100 µg/ml RITC-NCs. The cells were then washed by PBS (1 mL) for three times. Cells 
were then fixed with 4% paraformaldehyde and subsequently imaged on a 37 °C with 
confocal laser scanning microscope. Nucleus was stained by DAPI. Actins were stained 
with phalloidin-Alexa Fluo488. Control samples without nanoparticle addition were also 
imaged.  
 
Quantitative analysis by microplate reader. MCF-7 cells were seeded in 24-well plates at 
a density of 5×104 cells/well and cultured for 24 h. After that, the culture medium was 
replaced by opti-MEM and pre-incubated at 37 °C for 30 min followed by addition of 
RITC-labeled NCs of 50 or 200 nm at 100 μg/mL. After incubation at 37 °C for 2 h, the 
medium was discarded, and cells were rinsed with PBS (1×) for three times. The cells 
were then lysed with 500 μL/well of 0.5% SDS (pH 8.0) at room temperature for 20 min. 
Content of RITC-labeled NCs in the lysate was quantified by microplate reader (ex 570 
nm, em 590 nm). Protein content was measured using the Pierce BCA protein assay 
(Rockford, IL). A standard curve was obtained using a bovine serum albumin (BSA) 
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solution. Uptake level was expressed as percentage of the total fluorescence present in the 
feed solution normalized by mg of protein. 
 
4.2.3. Cytotoxicity of Cpt-NCs by MTT assay. 
MCF-7 cells were seeded in 96-well plates at 3,000 cells/well and grown in culture 
medium containing 10% FBS at 37°C for 24 h in a humidified 5% CO2 atmosphere. The 
medium was replaced with fresh medium containing Cpt, Cpt-silica NCs or blank silica 
NCs in concentrations ranging from 1 nM to 10 µM of Cpt or equivalent Cpt. At each 
concentration of six wells per plate were treated. The cell viability was determined by the 
MTT assay after 72 h. The standard MTT assay protocols were followed thereafter.35  
 
4.2.4. In vivo tumor reduction study in a subcutaneous murine lung cancer model 
Comparing Cpt200 and Cpt50 with slow release profile. Prior to use in tumor 
inoculation, Lewis Lung Carcinoma (LLC) cells were cultured in DMEM medium 
containing 10% FBS (Fetal Bovine Serum), 100 units/mL aqueous Penicillin G and 100 
μg/mL streptomycin. Female C57BL/6 mice, 8-week old, were anesthetized, shaved and 
injected in the right flank with 1×106 LLC cells suspended in a 1:1 mixture of HBS buffer 
and matrigel (BD Biosciences, Franklin Lakes, NJ, USA). The injection protocol is 
summarized in Table 4.1. After two weeks, when tumors had reached ~300 mm3, mice 
were divided into five groups (n=5) so as to minimize weight and tumor size difference. 
Tumor-bearing mice were treated by intravenous injection of PBS (1×), Cpt50 (25 
mg/kg) or Cpt200 (25 mg/kg). After dosing, the animals were monitored closely, and 
measurements of the tumor size for each animal were performed at regular intervals using 
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calipers without knowledge of which injection each animal had received. If body weight 
loss was beyond 20% of predosing weight, the animals were euthanized. When the tumor 
load reached 2000 mm3 or the animal had become moribund, the mouse was sacrificed. 
Data reported are average ± standard error of the mean (SEM). Statistical analysis was 
performed using a Student’s t-test (two-tailed), and p-values < 0.05 were considered 
statistically significant.  
 
Comparing Cpt-N200 and Cpt-N20 with fast release profile. Female C57BL/6 mice, 8-
week old, were anesthetized, shaved, and prepared for implantation of the tumor cells.  
LLC cells were collected from culture, and 1 × 105 cells suspended in a 1:1 mixture of 
HBS buffer and matrigel were then injected subcutaneously into right flank of a mouse. 
After two weeks when tumors had reached ~40 mm3, mice were divided into three groups 
of five mice, minimizing weight and tumor size difference. Tumor-bearing mice were 
treated by intravenous injection (Q4d × 3) of PBS (1×), Cpt-N200 (40 mg/kg) or Cpt-N20 
(40 mg/kg). After dosing, the animals were monitored closely, and measurements of the 
tumor size for each animal were performed using calipers without knowledge of which 
injection each animal had received. The tumor volume for each time point was calculated 
according to the formula (length)×(width)2/2, where the long axis is the length, the short 
axis is the width.  If body weight loss is beyond 20% of predosing weight, the animals 
were euthanized. When the tumor load reached 1000 mm3 or the animal had become 
moribund, the mouse was sacrificed. Data presented are average ± standard error of the 
mean (SEM). The statistical analysis was undertaken using a Student’s t-test (two-tailed), 
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4.2.6. In vivo biodistribution study in a xenograft human breast tumor model. 
Athymic nude mice bearing MCF-7 tumors (size: ~7 mm × 7 mm) were divided into 
groups of three, minimizing tumor size variations between groups. Mice were injected 
intravenously with 64Cu labeled silica NCs, 200, 50 or 20 nm in diameter, at a dose of 80 
mg silica/kg. Mice were placed on the micro-CT imaging bed and kept in the same 
isoflurane flow. A dynamic PET scan was acquired for 1 h (60 min acquisition time, 
reconstructed as 60 frames at 60 seconds/frame). The micro-CT scan (80keV/500uA X-
rays energy, 360 projections, 360 degrees, pixel size: 75 µm) was used for determining 
the anatomical localization of LNs. Static micro-PET scans were acquired at selected 
time points (6, 24 h p.i.) together with micro-CT scans for anatomical co-registration. 
The obtained micro-PET and micro-CT images were reconstructed using ordered subset 
expectation maximization (OSEM) and cone-beam algorithms with existing commercial 
software (Inveon Acquisition Workspace and Cobra Exxim, respectively). Micro-PET 
images were processed using 3-D median filtering and fused with micro-CT images. To 
quantify the radioactivity of 64Cu in LNs, complex irregular volumes of interest (VOIs) 
were drawn on the micro-CT images and registered with the micro-PET images to 
determine mean counts in each VOI. To minimize partial volume effects, the anatomical 
borders of the organs were not included. The radiotracer activity from each VOI was 
normalized by injected dose and expressed as percent of the decay-corrected injected 
activity per cm3 of tissue, which can be approximated as percentage %I.D./g assuming 
the density of tissue is ~1 g/cm3. The initial total injected activity was determined by dose 




4.2.7. Radioactivity measurement with γ-counter 
Mice were euthanized and dissected after the final micro-PET/CT imaging session (24 h 
p.i.). The LNs at both sides were collected, weighed and measured for radio activity 
(64Cu) with Wizard2 γ-counter using appropriate energy window at photopeak of 511 
keV. Raw counts were corrected for background, decay, and weight. Corrected counts 
were converted to microcurie (µCi) per gram by use of a previously determined 
calibration curve by counting 64Cu standards. Activity in each collected tissue sample 
was calculated as percentage of injected dose per gram of tissue (%I.D./g). For this 
calculation, the radio activity in tissue was corrected for decay to the time of γ-well 
counting. 
 
4.2.8. In vivo tumor metastasis prevention study in a murine breast cancer model 
Monitoring the progression of metastasis using BLI. Female BALB/c mice received 1 
×105 4T1 cells via the lateral tail vein at Day 0, and then were randomized into 5 groups 
with 9-12 mice per group. The mice were treated three times (every four days) started 
from Day 1 by intravenous injection of PBS (1×), PEGylated blank silica NPs (50 nm in 
diameter, equivalent silica amount as Cpt-N200, Cpt-N50 and Cpt-N20 groups), Cpt-
N200 (20 mg/kg), Cpt-N50 (20 mg/kg), Cpt-N20 (20 mg/kg) and free irinotecan (100 
mg/kg) through i.p. injection every week. The injection protocol is summarized in Table 
4.4. Food intake and body weight were measured every 4 days. The study was terminated 
at Day 14 and internal organs were collected at necropsy for evaluation. BLI was 
conducted every 4 days to monitor the progression of metastasis induced by luciferase-
engineered 4T1 cells. Each mouse was intraperitoneally injected with D-luciferin 
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potassium (0.15 g/kg body weight) 3 minutes prior to imaging, and then anesthetized 
with isoflurane/oxygen. A grey-scale image of the mouse was first recorded with dimmed 
light. Photon emission was then integrated for 3 minutes using the imaging software 
Piper Control (Stanford Photonics, Palo Alto, CA) and visualized in pseudo-color. To 
localize bioluminescent signals that indicated luciferase-engineered 4T1 tumors, grey-
scale images of mouse body and bioluminescent signals of metastatic tumors were 
merged using Image J (NIH) and Photoshop (Adobe, San Jose, CA). Bioluminescent 
signals were semi-quantified by measuring the integrated density in the area shaped 
around each site of photon emission using Image J. The threshold for measurement was 
set as 5,000 empirically.  
 
Scoring of metastases and histology analysis. At necropsy, internal organs including 
lungs, kidneys, livers and spleens were excised and fixed in 10% formalin. Metastatic 
4T1 tumors on the lungs were evaluated by two methods: tumor nodule formation and 
tumor spread on the surface of the lungs. Metastatic 4T1 tumor nodules on the lungs were 
counted with the aid of a dissecting microscope. Metastatic 4T1 tumor spread on the 
lungs was evaluated as following: lungs with over 90% surface occupied by tumors 
scored by 5; lungs with 70-90% surface occupied by tumors scored by 4; lungs with 50-
70% surface occupied by tumors scored by 3; lungs with 30-50% surface occupied by 
tumors scored by 2; lungs with less than 30% surface occupied by tumors scored by 1. In 
the present study, lungs with scale 1 were outliers, thus being excluded from analysis. 
Macro-metastatic tumors on organs other than the lungs were scarce, thus being 
evaluated only histologically. Internal organs including lungs, kidneys, livers and spleens 
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were embedded in paraffin, sliced into 5 µm and stained with H&E for histology analysis. 
All the data were analyzed using one-way ANOVA (OriginPro) with post hoc Fisher’s 
LSD test. 
 
4.2.9. In vivo biodistribution study in a murine breast cancer model 
Female BALB/c mice with metastatic 4T1 tumors in lungs were prepared similarly as 
abovementioned and were divided into groups of three. Mice were injected intravenously 
with 64Cu labeled silica NCs, 200, 50 or 20 nm in diameter, at a dose of 80 mg silica/kg. 
Normal BALB/c mice without tumors were injected with 64Cu labeled silica NC (50 nm) 
as control. Mouse organs: heart, lung, liver, spleen, kidneys, stomach, intestines and 
tumors were harvested after all the imaging experiment. The radioactivity of tissues was 
assayed by a γ-counter. To determine 100% dose, diluted solution of the corresponding 
NCs was measured along with tissues at the same instrument settings. Data are presented 
as percent injected dose per gram of tissues. The statistical analysis was undertaken using 
a Student’s t-test, and p-values < 0.05 were considered statistically significant. Data are 
presented as average ± standard deviation.  
 
4.3. Results and Discussion 
4.3.1. Size dependent efficacy in a subcutaneous murine lung cancer model 
Given the preferential cellular internalization, tumor accumulation and penetration of 50 
nm NCs over 200 nm NCs (see studies in Chapter 3), I expect that the smaller NCs 
should also show improved antitumor efficacy in vivo. To demonstrate this, I evaluated 
the antitumor efficacy of Cpt-NCs of 50 and 200 nm against Lewis lung carcinoma (LLC) 
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tumors induced by s.c. injection of LLC cells into the flank of C57BL/6 mice. After 
tumors reached ~300 mm3 in size, the animals were divided into three groups (n=5) to 
minimize body weight and tumor size differences among the groups. Next, using 
unconjugated Cpt as a reference point, the following regimens were administrated by a 
single i.v. injection: a) PBS; b) Cpt50, 25 mg/kg; and c) Cpt200, 25 mg/kg. The tumor 
size and body weight were subsequently monitored for 12 days post-injection. As 
expected, the animals that received a single i.v. injection of Cpt50 showed a statistically 
significant (*p < 0.05, two tailed t-test) delay in tumor growth relative to the PBS group 
(Figure 4.1a). Meanwhile, no statistical significance was observed for the Cpt200 group 
relative to the PBS group. A statistical significance was also observed between the Cpt50 
and Cpt200 groups from Day 7 to Day 12. Collectively, this data indicated that Cpt50 had 
significantly higher efficacy than Cpt200 in inhibiting subcutaneous LLC tumors in mice. 
No acute body weight drop was observed for all the groups, suggesting no acute toxicity 
for Cpt-NCs of both sizes (Figure 4.1b).  
 
Figure 4.1 In vivo tumor reduction study in a subcutaneous murine lung cancer model. a, Delay 
and inhibition of LLC tumor growth in C57Bl/6 mice with treatment of Cpt-NC with different 
sizes. Data display as mean of relative tumor size. Statistical analysis by T-Test (two tail, *p<0.05, 
n.s.: not significant). b, Body weight monitoring over the study. 
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The results presented here clearly demonstrated that the size of nanomedicine could 
greatly impact the overall antitumor efficacy in vivo. Specifically, Cpt50 showed 
significantly improved antitumor efficacy as compared to Cpt200. The enhanced efficacy 
of smaller drug-NCs is likely due to the improved tumor accumulation and penetration in 
vivo, as well as enhanced cellular internalization efficiency and increased cytotoxicity of 
small NCs compared to their larger counterparts. Although the cytotoxicity of Cpt50 and 
Cpt200 was not dramatically different in vitro—IC50’s of 510 nM and 800 nM, 
respectively—the difference in in vivo antitumor efficacy was obvious, suggesting that 
the enhanced tumor accumulation and penetration are likely the source of the improved 
performance. As demonstrated in the ex vivo tumor study, the 50 nm NCs had 
substantially faster passive diffusion in tumor tissues. However, the more efficient 
cellular internalization of 50 nm NCs is also important for the NCs to achieve prolonged 
retention in tumors, ultimately leading to higher levels of drug released within tumor 
tissue and cancer cells.  
 
Table 4.1 Dosing protocol for the efficacy study in a subcutaneous murine lung cancer model. 
 
[a] PBS and two Cpt-NC using selected dosing schedules were administered to C57Bl/6 mice 
bearing LLC tumors. Five mice were used in each group. [b] Doses are equivalents of Cpt.  
 
Because Cpt-NCs with thiol-ester linker (with 2 in Scheme 2.1, Chapter 2) between Cpt 




Dose (mg of 
Cpt/kg)[b] Route Schedule
1 PBS 0 i.v. Q4D×3
2 Cpt-N200 40.0 i.v. Q4D×3
3 Cpt-N20 40.0 i.v. Q4D×3
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LLC tumor growth was not prominent in the above study. With much faster release 
profile for Cpt-N-NCs with amino-ester linker (with 3 in Scheme 2.1, Chapter 2), Iexpect 
they have better anticancer efficacy than Cpt-NCs. Thus, I next compare the efficacy of 
Cpt-N-NCs with amino-ester linker using murine models of LLC tumor developed by s.c. 
injection of LLC cells in the flank of C57BL/6 mice. After tumors have developed to ~40 
mm3, I performed comparative efficacy studies by dividing animals into five groups (n=5) 
in a way to minimize weight and tumor size differences among the groups. Cpt as a 
reference point, the following regimens were administrated by i.v. (Q4d × 3) injection: 1), 
PBS; 2), Cpt-N200, 40 mg/kg; 3), Cpt-N20, 40 mg/kg (Table 4.1). The mice were 
sacrificed at Day 12. As compared to PBS group (Figure 4.2), Cpt-N200 showed 
negligible efficacy of inhibiting tumor growth (not significant at Day 12). However, Cpt-
N20 efficiently reduced the tumor burden to ~1/4 of the PBS control with statistical 
significance (*p≤0.05, compared to PBS group at Day 12).  Clearly, Cpt-N20 has better 
efficacy than Cpt-N200 (**p≤0.01 at Day 12) for inhibition of LLC tumor growth. The 
improved antitumor efficacy of Cpt-N20 may be ascribed to its enhanced tumor 
penetration property as compared to larger NPs. This result demonstrated that the size of 
nanomedicine played a crucial role in determining the in vivo therapeutic efficacy for 
cancer. However, the xenograft LLC tumor model grew too rapidly, which makes it 

















Figure 4.2 Size effect on in vivo antitumor activity to LLC tumors in C57Bl/6 mice. C57Bl/6 
mice bearing LLC tumors were injected with Cpt-N20, Cpt-N200 and PBS through tail vein when 
the tumors reached ~40 mm3. Three doses was administrated on Day 1, Day 5 and Day 9. Tumor 
sizes at Day 12 are shown as average±SEM. (Student T-test (two-tailed): n.s., not significant, 
0.01< *p ≤ 0.05; **p ≤ 0.01).  
 
4.3.2. Size dependent efficacy in a xenograft human breast tumor model.  
Table 4.2 Antitumor efficacy study in athymic nude mice bearing subcutaneously implanted 
MCF-7 tumors.[a] 
 
[a] Each mouse was euthanized when the tumor size reached the end point (700 mg) or at day 99. 
TTE is the time (days) to the end point (1500 mg).TTE = time to endpoint (Days), 700 mg; 
TGD= T-C =Difference between TTE (Days) of treated versus control group; %TGD = [(T-C)/C]; 
TR = Treatment Related Death; NTR = Non Treatment Related Death; NEU is the number of 
mice euthanized after the end point had been reached. 
 
As the LLC tumor model grows too fast to allow the careful comparison of the efficacy 
of silica NCs of different sizes. I further performed the tumor reduction studies of the size 













TGD (day) %TGD No. of TR No. of NTR
No. of 
EU
1 PBS 5 20 0 i.v. Q4d × 3 48.1 -- -- 0 1 4
2 Blank NP 6 24 0 i.v. Q4d × 3 49.8 1.8 3.7% 0 2 4
3 Irinotecon 6 24 100 mg/kg i.p. Qwk × 3 99.0 51.0 106.0% 1 0 1
4 Cpt-N200 6 24 20 mg/kg i.v. Q4d × 3 54.0 6.0 12.4% 0 0 6
5 Cpt-N50 6 24 20 mg/kg i.v. Q4d × 3 88.6 40.6 84.4% 0 2 4























was performed in accordance with the protocol illustrated in Table 4.2. Six groups of 
athymic nude mice (5-6 mice with 20-24 tumors per group) bearing ~40 mm3 xenograft 
MCF-7 breast tumors were treated differently. Results for the study that include median 
TTE values, average tumor burden, treatment response, and deaths are also summarized 
in Table 4.2. The tumor growth rate was also closely monitored by measuring the tumor 
size. The tumor size data are shown in Figure 4.3. All the data points were statistically 
compared for each pair of the groups using one-way ANOVA as shown in Table 4.3. In 
PBS group, one NTR death was observed on Day 60. Tumors in the other control mice 
grew to the end point size of 700 mg, yielding a median TTE of 48.1 days (Table 4.2). As 
compared to PBS, only Group 2 (blank silica NP, 50-nm) didn’t show any efficacy, with 
a median TTE of 49.8 days (1.8 day TGD relative to control mice) and similar tumor 
growth curve as PBS group (no statistical significance observed; Figure 4.3a). All mice 
died or were euthanized by Day 60. The Kaplan-Meier plot of Group 2 is also similar as 
PBS group (Figure 4.4). These result indicated the blank silica NPs didn’t have any 
toxicity to the tumor.  
 
 
Figure 4.3 In vivo antitumor efficacy study in athymic nude mice bearing xenograft MCF-7 
tumors. a, MCF-7 tumors was induced in mice by implanting MCF-7 breast cancer cells s.c. on  
























































(Figure 4.3 cont.) the flanks of athymic nude mice and allowing the tumors to develop to 
appreciable size over 20 days (~50 mm3). Three doses of (i) PBS buffer, (ii) blank silica NPs, (iv) 
Cpt-N200, 20 mg/kg, (v) Cpt-N50, 20mg/kg and (vi) Cpt-N20, 20 mg/kg, were administrated i.v. 
on Day 0 and Day 4 and Day 8 respectively for each group. Irinotecan (iii, 100 mg/kg) were 
administrated i.p. on Day 0 and Day 7 and Day 14. Data represent average ± SEM of 24 tumors 
per group and are analyzed by One-way ANOVA (Fisher) (n.s., not significant, 0.01< *p ≤ 0.05; 
**p ≤ 0.01). b, The body weight of mice were monitored during the whole study to evaluate if 
any acute toxicity caused by the treatment. 
 
Table 4.3 Statistical analysis of the tumor size.[a] 
 
[a] All the data were analyzed using one-way ANOVA (OriginPro) with post hoc Fisher’s LSD 
test. Statistical P-value between two treatment groups for each measurement was calculated. The 
first column lists the two treatment groups (A and B) to be compared. If the overall F ratio was 
significant, the means of different treatment groups were compared using Fisher’s LSD test. P-
value<0.05 was  considered statistically significant (significant: p<0.05, denoted as 1 in the table; 
not significant: p≥0.05, denoted as 0 in the table).     
 
All the other groups including the clinic drug, irinotecan, showed efficacy of tumor 
growth inhibition with statistical significance (Figure 4.3a and Table 4.3). Irinotecan as a 
clinic standard showed prominent efficacy with extended survival time (with TTE of 100 
days). The tumor growth curve also gives clear evidence of tumor growth inhibition with 
statistical significance from Day 8 as compared to PBS group (Figure 4.3a). However, it 
is noticeable the significant toxicity was also observed for the mice treated with 
Group A Vs. Group B Days post injection
0 2 4 6 8 10 14 18 22 26 30 34 40
SiO2-NP  PBS 0* 0 0 0 1 0 0 0 0 0 0 0 0
Irinotecan  PBS 0 0 0 0 1 1 1 1 1 1 1 1 1
Cpt-N200  PBS 0 0 0 0 1 1 0 1 1 1 1 1 1
Cpt-N50  PBS 0 0 1 1 1 1 1 1 1 1 1 1 1
Cpt-N20  PBS 0 0 1 1 1 1 1 1 1 1 1 1 1
Irinotecan  SiO2-NP 0 0 0 0 1 1 1 1 1 1 1 1 1
Cpt-N200  SiO2-NP 0 0 0 0 0 0 1 1 1 1 1 1 1
Cpt-N50  SiO2-NP 0 0 0 1 1 1 1 1 1 1 1 1 1
Cpt-N20  SiO2-NP 0 0 0 1 0 1 1 1 1 1 1 1 1
Cpt-N50  Cpt-N200 0 0 1 1 1 0 1 1 1 1 1 1 1
Cpt-N20  Cpt-N200 0 0 0 0 0 0 0 1 1 0 1 1 1
Cpt-N20  Cpt-N50 0 0 0 0 0 0 0 0 0 0 0 0 0
Cpt-N200  Irinotecan 0 0 0 0 1 1 1 1 1 1 1 1 1
Cpt-N50  Irinotecan 0 0 1 1 0 0 0 0 0 0 0 0 0
Cpt-N20  Irinotecan 0 0 0 1 0 0 0 0 0 0 0 1 1
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irinotecan. One TR death was observed on Day 1 and significant bodyweight drop was 











Figure 4.4 Kaplan-Meier plot for all groups. Loss of mice was due to treatment-related death, 
non treatment-related death or euthanasia after the end point (700 mg or body weight drop≥20%) 
had been reached. 
 
 
Figure 4.5 Size effect on cellular internalization and cytotoxocity. a, Cellular uptake of RITC-
NCs of different sizes by MCF-7 cells. b, In vitro cytotoxicity to MCF-7 cells treated with Cpt-N-
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tumor size as compared to PBS were observed as early as Day 4 (Figure 4.3a and Table 
4.3). There was no statistical significance of tumor size between Cpt-N50 and Irinotecan 
groups. Obviously, Cpt-N200 is less efficacious as compared to Cpt-N50 and Cpt-N20. 
Although the survival of Cpt-N200 is similar as Cpt-N20 (Figure 4.4), Cpt-N20 showed 
enhanced inhibition of tumor growth with statistical significance (Figure 4.3a and Table 
4.3). The TTE of Cpt-N200 and Cpt-N20 are 54.0 days and 66.1 days respectively (Table 
4.2). Both groups showed no significant toxicity (Figure 4.3b). Although there are no 
statistical significance by comparing the tumor sizes of Cpt-N50 and Cpt-N20 groups 
(Figure 4.3a and Table 4.3), Cpt-N50 showed better survival of the mice (Table 4.2 and 
Figure 4.4). The result indicated that Cpt-N50 outperformed Cpt-N200 and Cpt-N20 
suggesting that 50 nm may be the optimal size for the treatment of MCF-7 tumor.  
 
4.3.3. Size effect on cellular internalization and cytotoxicity 
To investigate how the size of NP impacts the overall efficacy, I first probed the NP size 
effect on cellular internalization using silica NCs with distinct sizes. RITC-NCs of six 
different sizes, 200.0, 87.5, 68.2, 50.9, 38.0, 20.0 nm in diameter, were incubated with 
MCF-7 cells at 37 °C for 1 h to investigate the size effect on cellular internalization 
(Figure 4.5a). The cell uptake level was presented as the percentage of the total feeding 
amount normalized by the total mass of the protein in the cells (%/mg protein). Generally 
smaller NCs were internalized more efficiently by MCF-7 cells. The cellular 
internalization for NCs of 50.9, 38.0 and 20.0 nm was 3.5, 4.1 and 4.5 fold respectively 
of that of 200-nm NCs. However, when the NC size was controlled ≤50 nm, the cell 
uptake levels were close and the differences were not statistically significant between 
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groups (22.6, 26.7, 29.5%/mg protein for NCs of 50.9, 38.0, 20.0 nm respectively; T-test, 
p>0.05 when comparing each pair of groups). To confirm that the RITC-NCs were 
internalized by MCF-7 cells rather than just associated to cell surface, the MCF-7 cell 
treated with RITC-NCs (37 °C for 1 h) were stained with DAPI (blue) and phalloidin-
Alexa Fluo488 (green) to label the nucleus and actin respectively (Figure 4.6).  These 
cells were examined with confocal microscope to analyze the intracellular distribution of 
the RITC-NCs (red) in MCF-7 cells. Clearly, the RITC-NCs were internalized and 
distributed dominantly in the cytoplasm of the cells. The internalized RITC50 and 
RITC20 were much more than RITC200 in the representative images. The results suggest 
that the NCs ≤50 nm can be internalized much more efficiently by MCF-7 cancer cells 
than larger NCs. The overall cytotoxicity of Cpt-NCs of different sizes was evaluated and 
compared with free Cpt using MTT assay with MCF-7 breast cancer cells (Figure 4.5a). 
There is no statistical significance between the IC50’s of Cpt-NCs with different sizes 
suggesting that the cytotoxicity is not the reason for the different in vivo efficacy.  
 
4.3.4. Size dependent biodistribution in a xenograft human breast tumor model. 
The efficacy data of MCF-7 tumor model clearly indicate the size importance of 
nanomedicine. To understand the role of size on biodistribution, silica NCs of different 
sizes were labeled with 64Cu for biodistribution study using PET/CT imaging technique 
(Figure 4.7). 64Cu labeled silica NCs of 200, 50, or 20 nm in diameter were i.v. 
administered through tail vein to athymic nude mice bearing MCF-7 tumors. The total 
injection per mouse in terms of radioactivity was measured using gamma counter. Whole 
body images were taken by a PET/CT imaging system at 10 min, 6 h and 24 h post 
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injection (p.i.). Figure 4.7a shows that clear tumor accumulation was observed for mice 
treated with silica NCs of 50 and 20 nm (indicated by yellow circle and arrow), while 
nearly negligible amount of fluorescence was observed at the tumor area of the mouse 
treated with silica NCs of 200 nm. All the tumors as well as major organs were harvested 
after the mice were euthanized and quantified for radioactivity ex vivo (Figure 4.7b). The 
values of I.D.%/g of tumor at 24 h post injection for the 200, 50 and 20 nm NC group 
were 0.88 ± 0.38, 1.62 ± 0.20 and 1.31 ± 0.37 (average ± SD; n=5) respectively. The 
accumulation of 50-nm NCs and 20-nm NPs in tumor is 1.85 and 1.50 fold respectively 
of 200-nm NCs with statistical significance (*p<0.05). Accumulation of 50-nm NPs and 
20-nm NPs in liver are also slightly higher than 200-nm NPs with significance (Figure 
4.7b).  This result indicated that smaller NPs are preferred for passive tumor targeting 
through EPR effect. The enhanced tumor accumulation of smaller NCs is likely ascribed 
to the better efficacy for MCF-7 tumor growth inhibition.  
 
















1 PBS 9 20 0 i.v. Q4d × 3
2 Irinotecon 12 24 100 mg/kg i.p. Qwk × 3
3 Cpt-N200 9 24 20 mg/kg i.v. Q4d × 3
4 Cpt-N50 7 24 20 mg/kg i.v. Q4d × 3















































































established by i.v. injecting 4T1 cells (105 cells; luciferase engineered) to the mice. To 
monitor the progression of metastasis induced by injection of 4T1 cells on Day 0 via the 
lateral tail vein into mice, BLI was conducted every 4 days post cell injection until the 
end of the study. Cpt-N200, Cpt-N50 and Cpt-N20 (20 mg Cpt equivalent/kg) were i.v. 
injected into mice on Day 1, Day 5 and Day 9 (Table 4.4). Irinotecan, a clinical drug, 
which has a similar structure as camptothecin was used as a positive control in the study. 
As shown in Figure 4.8, no bioluminescent signal was detected in all the groups on Day 
4. On Day 8, BLI images showed distinct area of photon emission localized on the lungs 
in the experimental groups, suggesting metastatic 4T1 tumor growth in the lung area 
(Figure 4.8). On Day 12, the size of the area of photon accumulation in the PBS, Cpt-
N200 and Cpt-N20 groups increased progressively with the intensity of the 
bioluminescent signal increased markedly as well (Figure 4.9b). The increase in the size 
and intensity of photon accumulation was much less remarkable in the groups treated 
with Cpt-N50 and irinotecan. As shown in Figure 4.9a, semi-quantification of 
bioluminescent signals on Day 12 by measuring the integrated intensity in the area 
shaped around each metastatic site showed that administration of Cpt-N50 significantly 
inhibited the progression of metastasis when compared to the PBS group (*p<0.05). This 
inhibitory effect of 50-nm silica NCs was comparable to the effect of the clinic drug, 
irinotecan, while administration of Cpt-N200 and Cpt-N20 did not inhibit the progression 
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0.8, 9.9 ± 1.1 and 8.7 ± 0.8 (average ± SD; n=5) respectively. The accumulation of NCs 
in metastatic tumor models was significantly higher than in the normal mouse without 
metastatic lungs (4.9 ± 0.5). The accumulation of 50-nm NCs was slightly higher than 
200-nm NCs and 20-nm NCs with statistical significance (*p<0.05). This result indicated 
that the enhanced tumor accumulation in metastatic lungs of 50-nm NCs is likely 
ascribed to the better efficacy for 4T1 tumor metastasis.  
 
Figure 4.13 In vivo biodistibution studies in BALB/c mice bearing 4T1 metastatic lung tumors. 
Balb/c mice 4T1 metastatic lung tumors were injected intravenously with 200, 50 and 20-nm 
silica NCs labeled with Cu-64. Mice were euthanized 24 h post injection. a. Organs were 
collected and measured for radioactivity by gamma counter. b, Metastatic lungs were also 
collected and measured similarly and compared with a normal lung tissue (injected with 50-nm 
Cu-64 labeled silica NC). (average ± SD; n=3; *p<0.05). 
 
4.4. Conclusions 
In Chapter 3, I have performed thorough studies to investigate the size effect of 
nanomedicine on the performance of overcoming different biological barriers. In this 
study, I formulated the drug contained Cpt-NCs with excellent size control to study the 























































that Cpt-NCs of 50 nm outperformed the NCs of other sizes not only in inhibition of 
primary tumor growth but also the prevention of tumor metastasis. These observations 
strongly emphasize the importance of controlling the size of nanomedicine ≤50 nm to 
achieve enhanced efficacy. Using the novel drug-silica chemistry described in this report, 
I can easily prepare monodisperse Cpt-NCs ≤50 nm with excellently controlled size. This 
formulation strategy holds great potential for further improvement in cancer therapy via 
size-controlled nanomedicine. I foresee such drug-silica NCs as a real, clinically relevant 
drug delivery system which not only offers a unique platform for the further study of the 
size effect of nanomedicine on the treatment of different cancers, but also can be readily 
prepared with the optimized size on a larger scale for potential clinic applications. 
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CHAPTER 5  
SILICA NANOCONJUGATE FOR DIAGNOSIS OF CANCER METASTASIS 
 
5.1. Introduction 
Metastases are ascribed for 90% of human cancer deaths.1-3 Most solid tumors 
metastasize through the lymphatic system, in which the sentinel lymph node (LN) is 
typically the first site reached by the disseminating malignant cancer cells.4, 5 The 
accurate detection of LN metastasis is crucial for correct tumor staging and therapeutic 
decision-making.6-11 The current gold standard method for LN assessment is surgical 
lymphadenectomy. However this method is invasive with extended nodal dissection in 
patients and could give false negative result if the LN is missed.12, 13 A noninvasive 
imaging technique of LN is urgently desired to improve the accuracy of tumor staging 
and further provide intraoperative guidance.14, 15 Some modern techniques has emerged 
for noninvasive sentinel LN imaging, such as near infrared (NIR) fluorescence imaging, 
computed tomography (CT), magnetic resonance imaging (MRI), positron emission 
tomography (PET), ultrasound and photoacoustic imaging.15-19 Among the above-
mentioned imaging techniques, however, no single modality is perfect and sufficient to 
gain all the necessary information for LN assessment because each has its inherent pros 
and cons.20 For example, PET is so far the most sensitive and specific technique for in 
vivo molecular imaging but suffers from low spatial resolution.21 Fluorescence imaging 
has high resolution and allows visualization but its application is limited by poor tissue 
penetration compared to PET or MRI.17 Therefore, the combination of these two 
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techniques provides the ability for both noninvasive imaging with high sensitivity (PET) 
and intraoperative guidance with excellent resolution (fluorescence). 
 
Silica nanoparticles (NPs) are widely used for medical imaging applications because of 
the high biocompatibility and optically transparent nature of silica.22-27 I developed a 
precisely size controlled silica nanoconjugate (NC) as a versatile platform allowing 
conjugation with a variety of functional modalities (ex. drugs and fluorescence dyes).28 
The robust silane chemistry and the formulation strategy will potentially allow the 
construction of multifunctional NCs, including multi-modal imaging probes for in vivo 
applications. It is generally accepted that physicochemical properties, especially size of 
NP play a vital role in systemic biodistribution as well as lymphatic distribution.29-36 The 
excellent control over size makes these silica NCs ideal test subjects for the investigation 
of the size effect of NP in lymphatic system in order to identify the optimum size of 
nanoparticulate probe for improved metastatic LN imaging with the balance of efficient 
lymphatic uptake (smaller NP preferred) and sustained retention in LN (larger NP 
preferred).31  
 
Despite a large number of investigations on cancer targeting for primary tumors,37-39 very 
few attempts have been made so far to achieve active targeting for metastatic tumor 
specifically.40-43 Single-stranded oligonucleotides which can bind to target molecule with 
high specificity and affinity, named aptamer (Apt), has attracted a lot of attention recently 
for cancer targeting,  due to its stability against denaturation and biodegradation,  non-
immunogenicity and easy scalability as compared with antibody.44-48 The primary tumor 
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targeting capability of Apt has been demonstrated in several studies in vivo.46, 47 However, 
active targeting to lymphatic metastases using Apt has not yet been reported. Herein, I 
report a convenient, one-pot synthesis of PET and optical dual-modal imaging probe of 
precisely size-controlled silica NC for lymphatic imaging. Monodisperse silica NCs as 
small as 20 nm in diameter were demonstrated to show rapid and enhanced sentinel LN 
accumulation and thus were favored for efficient LN imaging as compared to the larger 
counterparts. To further improve the accuracy of discrimination of metastatic and normal 
LNs, 20-nm silica NC was functionalized with a 26-mer G-rich DNA Apt derived from 
AS1411 with high binding affinity to nucleolin (NCL), which is overexpressed on the 
plasma membrane of a number of breast cancer cells.49-53 The NCL-Apt functionalized 
dual-modal silica NC showed enhanced uptake in metastatic LNs in a murine breast 
tumor model thus can improve the detection efficiency for tumor metastasis. This Apt 
functionalized, size-controlled silica NC as a novel dual-modality imaging probe holds a 
lot of promise for targeted imaging of metastatic lymph nodes. 
 
5.2. Materials and Methods 
5.2.1. General 
All the chemicals including tetraethyl orthosilicate (TEOS, 99.999%) were purchased 
from Sigma-Aldrich (St Louis, MO, USA) unless otherwise noted. (S)-2,2',2'',2'''-(2-(4-
isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid 
(p-SCN-Bn-DOTA) was purchased from Macrocyclics, Inc. (Dallas, TX). mPEG5k-
triethoxysilane (PEG-sil) (Scheme 5.1) and Maleimide-PEG5k-SCM (MAL-PEG-NHS) 
was purchased from Laysan Bio (Arab, AL, USA). All olignucleotides used in this study 
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were purchased from Integrated DNA Technologies Inc. (Coralville, IA, USA) with 
following sequences: NCL-Apt: 5'-GGT GGT GGT GGT TGT GGT GGT GGT GGT 
TTT TTT TTT TTT TTT TT/3ThioMC3-D/-3'; Control DNA: 5'-GAG AAC CTG AGT 
CAG TAT TGC GGA GAT TTT TTT TTT TT/3ThioMC3-D/-3'. DNA concentration 
was measured by NanoDrop 2000 (Thermo Scientific, Wilmington, DE, USA). All the 
chemicals and DNA were used as received unless otherwise noted. All anhydrous 
solvents were purified by passing them through dry alumina columns and kept anhydrous 
using molecular sieves. Rhodamine B isothiocyanate (RITC)- or IR783-containing 
silanes were prepared as described in a previous paper.28 The sizes and monodispersities 
of silica nanoparticles were determined with a Hitachi S4800 high resolution Scanning 
Electron Microscope (SEM). ξ-potential was measured with a Malvern Zetasizer Nano-
ZS with a 633 nm laser (Malvern Instruments Ltd., Worcestershire, UK). Measurement of 
fluorescence spectra of silica nanoparticles was carried out in LS55 Fluorescence 
Spectrometer (Perkin Elmer, Santa Clara, CA, USA). Murine 4T1 cells engineered with 
firefly luciferase were provided by Dr. David Piwnica-Worms from Washington 
University (St. Louis, MO, USA). Cells were cultured in DMEM medium containing 10% 
Fetal Bovine Serum (FBS), 100 units/mL aqueous Penicillin G and 100 μg/mL 
streptomycin (Invitrogen, Carlsbad, CA, USA) at 37°C in 5% CO2 humidified air. Cells 
were harvested at 80% confluence with EDTA/trypsin, counted and re-suspended for 
experiments. The flow cytometry analysis of cells was conducted with a BD FACSCanto 
6 color flow cytometry analyzer (BD, Franklin Lakes, NJ, USA). Female C57BL/6 or 
BABL/c mice were purchased from National Cancer Institute (NCI, Frederick, MD, 
USA). Feed and water were available ad libitum. Artificial light was provided in a 12/12 
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hour cycle. The study protocol was reviewed and approved by The Illinois Institutional 
Animal Care and Use Committee (IACUC) of University of Illinois at Urbana 
Champaign. Micro-PET/CT imaging was performed with small animal dedicated 
Siemens Inveon PET-CT system (Siemens Healthcare, USA). Ex vivo measurement of 
the radio activity was conducted with 2480 Wizard2 Automatic Gamma Counter (Perkin-
Elmer, USA). The fluorescence intensity in the extracted lymph node was measured ex 
vivo at λem=800 nm with Odyssey infrared mouse imaging system (LI-COR, Lincoln, NE, 
USA). The flash frozen lymph node tissue was embedded with optimum cutting 
temperature (O.C.T.) compound (Sakura Finetek USA, Torrance, CA, USA) and 
sectioned with a Leica CM3050S cryostat and mounted on glass slides for histological 
analysis.  
 
5.2.2. Synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) 
containing silane (DOTA-sil)   
 
In a reaction vial containing 3-aminopropyltriethoxysilane (4.8 mg, 0.022 mmol) was 
added an anhydrous dimethylformamide (DMF) solution (0.5 mL) of DOTA-NCS (10 
mg, 0.018 mmol) and triethylamine (3.6 mg, 0.036 mmol). The reaction mixture was 
stirred for 4 h under nitrogen protection at RT. The solvent and triethylamine was 





5.2.3. Synthesis of Maleimide-PEG5k containing silane (MAL-PEG-sil)  
 
In a reaction vial containing 3-aminopropyltrimethoxysilane (4.4 mg, 0.020 mmol) was 
added an anhydrous DMF solution (1 mL) of MAL-PEG-NHS (17 mg, 0.004 mmol) and 
triethylamine (2.0 mg, 0.020 mmol). The reaction mixture was stirred for 4 h under 
nitrogen protection at RT. The solvent and triethylamine was removed by vacuum to give 
MAL-PEG-sil, which was used directly without further purification. 
 
5.2.4. General procedure for the preparation of dual modal silica nanoconjugates 
(NCs) 
The size controlled, dual modal silica NCs were prepared similarly as previously 
reported.28 The size of NC was controlled by the reaction condition (Table S1). For 
example, to prepare the NC200, methanol (1.0 mL), DI water (0.27 mL) and concentrated 
ammonia (0.24 mL) were mixed. TEOS (62.5 µL, 0.28 mmol) was then added to the 
solvent mixture and stirred for 10 min followed by the addition of a methanol solution 
(100 µL) of NIR-sil (2 mg, 2.2 µmol). The mixture was stirred at a stirring rate of 100 
rpm at RT under dark for 12 h to form the fluorescent core of the NC. Next, a methanol 
solution (200 µL) of DOTA-sil (2 mg, 2.6 µmol) was added to the reaction mixture and 
stirred for 10 min followed by the addition of PEG-sil (20 mg/mL, 100 µL) to modify the 
surface of NC. The mixture was further stirred for 6 h at the same stirring speed. The 
resulting NCs were collected by centrifugation at 15k rpm and washed by ethanol (3 × 1 
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mL) and redispersed in DI water or PBS (1×) right before use. To characterize the size, 
one drop of a dilute solution of NCs in ethanol on a silicon wafer was allowed to dry in 
air and then analysed by SEM at 5 kV. The hard core size of NC (200 nm in this case) 
was determined by measuring 100 particles on representative SEM images and averaging 
the sizes. Preparation of NCs with other sizes was similar but using different 
concentrations of TEOS, water and ammonia similarly as described in Chapter 2. 
 
5.2.5. Surface conjugation with DNA 
To conjugate the DNA to the NC surface, size controlled NCs were prepared similarly as 
described above except for that the surface of NCs were modified by MAL-PEG-sil (20 
mg/mL, 100 µL) (Scheme 1). For example, to conjugate the NC20 with NCL-Apt, NCL-
Apt (5 nmol) in 100 µL PBS (1×) was first mixed with tris(2-carboxyethyl)phosphine 
(100 nmol) and stirred for 2h at RT to reduce the disulfate bond at the 3’-end of DNA to 
give NCL-Apt with a free thiol group for conjugation. The reduced NCL-Apt (5 nmol, 
without further purification) was then added to the NC (5 mg, surface modified by MAL-
PEG-sil) in 250 µL PBS (1×). The mixture was stirred overnight at RT. The resulting 
NCs were collected by centrifugation at 15k rpm and washed by PBS (1×) (3 × 1 mL) 
and redispersed in PBS (1×) right before use. To determine the conjugation efficiency, the 
NCs were centrifuged down (15k rpm) and the DNA concentration in the supernatant was 
monitored with Nanodrop 2000 before and after the conjugation step. The size of NC was 
characterized with SEM and DLS as described above. The conjugation of Ctrl-DNA to 
the surface of NCs followed the procedure described above. RITC labeled NC20-Ctrl and 




5.2.6. DLS and ξ-potential measurements 
To measure the hydrodynamic size was measured with 90Plus Particle Size Analyzer by 
dispersing the NCs in PBS (1×) at concentration of 0.5 mg/mL. Measurements were 
taken at a 90° scattering angle. The ξ-potential of the NCs was determined with a 
Malvern Zetasizer. The freshly prepared NCs were dispersed in DI water to a 
concentration of 0.5 mg/mL.  
 
5.2.7. 64Cu labeling of NCs 
The 64Cu chloride (Washington University in at St. Louis, MO, USA) was mixed with 
silica NC (2 mg) in NH4OAc buffer (pH=5.5, 0.1 M, 0.3 mL) (Figure 5.2). The mixture 
was incubated for 1 h at 80 °C. To determine the labeling efficiency, the NCs were 
centrifuged down (15k rpm, 5 min) and the radioactivity in the supernatant and the 
precipitation was measured respectively. The 64Cu-labeled silica NCs were purified by 
centrifugation and washed by PBS (1×) once (1 mL). The purified 64Cu-labeled silica 
NCs were then re-suspended in PBS (1×) for injection. 
 
5.2.8. Stability of 64Cu labeling in serum 
The 64Cu labeled NCs was dispersed in 50% reconstituted human serum (Sigma-Aldrich, 
0.6 mg/mL), equally distributed to 9 vials with 0.1 mL NC solution per vial, and then 
incubated at 37 °C. At selected time intervals (0, 3, 6 h), three selected vial of each group 
were taken out of the incubator. The NC solution was centrifuged at 14k rpm for 5 min 
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and the supernatant was transferred to a nonradioactive tube for radioactivity 
measurement with γ-counter so as to determine the amount of disassociated 64Cu. 
 
5.2.9. Cellular internalization of NCs 
To examine cell uptake of Apt functionalized silica NC, NC20-Apt and NC20-Ctrl 
labeled with RITC were prepared as described in a previous paper.28 4T1 cells (2 × 105) 
were seeded in a 12-well plate for 24 h. RITC labeled NC20-Apt and NC20-Ctrl (100 
µ/mL) were incubated with the cells in opti-MEM (1 mL) for 2 h (37 °C). The cells were 
then washed with PBS (1 mL × 3) and detached via trypsinization. Cells were fixed with 
4% paraformaldehyde for flow cytometry analysis (1 × 104 cells analyzed, PE-A 
channel). Both the percentage of the fluorescent cells relative to the total analyzed cells 
and the mean fluorescence intensity of the total cells were assessed. All experiments were 
performed in triplicate. 
 
5.2.10. Micro-PET/CT imaging 
Fifteen minutes before the imaging experiment, mice were anesthetized by using ~2% 
isoflurane in induction chamber. 64Cu labeled NCs (~30 μCi) were injected via hocks. 
The volume used for the hock injection is 20 μL. Mice were placed on the micro-CT 
imaging bed and kept in the same isoflurane flow. A dynamic PET scan was acquired for 
1 h (60 min acquisition time, reconstructed as 60 frames at 60 seconds/frame). The 
micro-CT scan (80keV/500uA X-rays energy, 360 projections, 360 degrees, pixel size: 75 
µm) was used for determining the anatomical localization of LNs. Static micro-PET 
scans were acquired at selected time points (6, 24 h p.i.) together with micro-CT scans for 
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anatomical co-registration. The obtained micro-PET and micro-CT images were 
reconstructed using ordered subset expectation maximization (OSEM) and cone-beam 
algorithms with existing commercial software (Inveon Acquisition Workspace and Cobra 
Exxim, respectively). Micro-PET images were processed using 3-D median filtering and 
fused with micro-CT images. To quantify the radioactivity of 64Cu in LNs, complex 
irregular volumes of interest (VOIs) were drawn on the micro-CT images and registered 
with the micro-PET images to determine mean counts in each VOI. To minimize partial 
volume effects, the anatomical borders of the organs were not included. The radiotracer 
activity from each VOI was normalized by injected dose and expressed as percent of the 
decay-corrected injected activity per cm3 of tissue, which can be approximated as 
percentage %I.D./g assuming the density of tissue is ~1 g/cm3. The initial total injected 
activity was determined by dose calibrator before the injection.  
 
5.2.11. Radioactivity measurement with γ-counter 
Mice were euthanized and dissected after the final micro-PET/CT imaging session (24 h 
p.i.). The LNs at both sides were collected, weighed and measured for radio activity 
(64Cu) with Wizard2 γ-counter using appropriate energy window at photopeak of 511 
keV. Raw counts were corrected for background, decay, and weight. Corrected counts 
were converted to microcurie (µCi) per gram by use of a previously determined 
calibration curve by counting 64Cu standards. Activity in each collected tissue sample 
was calculated as percentage of injected dose per gram of tissue (%I.D./g). For this 





5.2.12. Fluorescence imaging 
Mice were euthanized and dissected after all the imaging experiments (24 h p.i.). The I-
LNs at both sides were collected, weighed and then fixed in 10% formalin. The I-LNs 
were imaged with Odyssey infrared mouse imaging system ex vivo. The fluorescence 
intensity of NIR labeled NCs in the extracted LN was measure at λem=800 nm (shown as 
green color) and quantified by the software. Autofluorescence from the tissue at λem=700 
nm was shown in red color. The overlay images were shown in Figure 5.5.  
 
5.2.13. Metastatic LN tumor model 
The tumor model was established in 10 week-old female BABL/c mice by subcutaneous 
injection of 1 × 105 of 4T1 cells transfected with firefly luciferase to the hock of both legs 
of mice.24, 54 Tumor progression was evaluated using a bioluminescence imaging (BLI) 
system (Stanford Photonics, Palo Alto, CA) with a dual micro-channel plate ICCD 
camera. Each mouse was intraperitoneally injected with D-luciferin potassium (0.15 g/kg 
body weight) 3 minutes prior to imaging and then anesthetized with isoflurane/oxygen 
gas. A grey-scale image of the mouse was first recorded with dimmed light. Photon 
emission was then integrated for 10 seconds using the imaging software Piper Control 
(Stanford Photonics, Palo Alto, CA) and visualized in pseudo-color. To localize 
bioluminescent signals that indicated luciferase-engineered 4T1 tumors, grey-scale 
images of mouse body and bioluminescent signals of metastatic tumors were merged 
using ImageJ (NIH) and Photoshop Elements (Adobe, San Jose, CA). At the end of the 
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can bind a radionuclide (e.g. 64Cu) for PET imaging. As silica is optically transparent and 
the excitation and emission light can pass through the silica matrix, NIR-sill is added 
immediately after the addition of TEOS (Scheme 5.1) to be stably embedded into the core 
of the silica NC.25, 55 Next, DOTA-sil is added to the NIR dye doped silica NC to enable 
the conjugation of DOTA on surface for chelating radionuclide for PET imaging. 
Afterward, a silane-containing polyethylene glycol (PEG-sil) is employed to graft PEG 
polymer to the surface in one pot synthesis as to impart steric stability to the silica NC. 
Surface PEGylation of nanomedicine or nanoparticulate imaging probe is important for 
long circulation, minimized non-specific absorption and staying non-aggregated in vivo.56 
Following this procedure, NIR- and DOTA-modified silica NCs of controlled sizes (200 
and 20 nm, denoted as NC200 and NC20) were successfully prepared (Figure 5.1a). 
These NCs showed strong fluorescence emission with λem= 802.5 and 808.0 nm for 
NC200 and NC20 respectively, which were similar as IR783 (Figure 5.1b).57, 58 Effective 
surface modification with DOTA was evidenced by the 　-potential measurement. Both 
NC200 and NC20 had negative charged surface (-34.8 and -36.3 mV respectively; Table 
5.1) at neutral pH (7.4) due to the surface bounded carboxyl groups of DOTA (Scheme 
5.1). These NCs were able to chelate copper-64 (64Cu, t1/2 = 12.7 h, β+: 17.4%) cations 
with high labeling efficiency (>60%, Table 5.1; Figure 5.2) and enhanced labeling 
stability in 50% reconstituted human serum to mimic the physiological condition (Figure 
5.1c). Up to ~80% of chelated 64Cu stayed associated with NC200 and NC20 over 6 h in 
serum solution at 37°C. Such silica NC, which serves as a platform for preparing 
nanoparticulate multimodal imaging probe, features synthetic convenience, flexibility, 
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for NC200 and NC20 respectively) (Table 5.1). Discrete and monodisperse sizes are the 
prerequisite for the investigation of the size effect of NP on its performance in biological 
systems. The excellent size control of the silica NC as a dual imaging modality allows us 
to study and understand the impact of NP size on lymphatic distribution so as to develop 
a size-optimized nanoparticulate imaging probe for highly efficient lymphatic mapping.  
 




[a] The hard core sizes were measured by SEM. D=Average diameter. SD=standard deviation; [b] 
CV=SD/D; [c] The hydrodynamic sizes and polydispersity index (PDI) were measured by 
dynamic light scattering (DLS); [d] The conjugation efficiency (C.E.) of Ctrl- or Apt-DNA was 
determined by quantifying the DNA concentration in the supernatant with Nanodrop by 
centrifuging down the NCs before and after the conjugation; [e] The number (No.) of DNA 
molecule per NC was calculated based on the feeding ratio of DNA to NC and C.E. value. Silica 
NC density was set as 2.56 g/cm3. SEM size were used as NC diameter; [f] The labeling 
efficiency (L.E.) of 64Cu was determined by quantifying the radioactiviy in the supernatant with 
gamma counter by centrifuging down the NCs before and after the labeling reaction. 
 
5.3.3. PET/CT imaging using the dual-modal silica nanoconjugates  
To explore the use of as prepared NCs for non-invasive PET/CT imaging of sentinel 
lymph nodes in vivo and identify the optimal size of nanoparticulate imaging probe for 
the most efficient lymph node draining, I investigate the lymphatic trafficking of 64Cu 
labeled NC200 and NC20 in normal C57BL/6 mice (Figure 5.3a). The mice received 
small-volume interstitial injections of these two NCs at the rear hocks of both sides in a 
single mouse (left: NC20; right: NC200). PET imaging was carried out to monitor the 
Name of NC 




64[f] (%)D ± SD (nm) CV/%[b] D ± SD (nm) PDI ± SD C.E.[d] (%) No. of DNA per NC[e]
NC200 198.7±11.8 5.94 238.0±3.3 0.026±0.014 - - -34.8 76.5
NC20 23.1±2.3 9.96 43.8±0.4 0.147±0.010 - - -36.3 63.1
NC20-Ctrl 22.9±1.9 9.56 59.6±0.4 0.064±0.013 73.2 8.6 -41.4 67.6
NC20-Apt 25.1±2.4 8.30 63.5±0.3 0.073±0.016 79.6 9.4 -38.3 66.9
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distribution of 64Cu labeled NCs at both sides starting from 10 min to 24 h post injection 
(p.i.) (Figure 5.3b). The position of popliteal lymph nodes (P-LNs), which are the closest 
lymph nodes to the injection sites, can be clearly identified in the CT images (yellow 
arrow, Figure 5.3b). In the overlay images of CT and PET shows noticeable radioactivity 
in the left P-LN as early as 12 min p.i. but not in the right P-LN. The kinetic profile of the 
accumulation of NCs in P-LNs was closely monitored during the first hour p.i. (Figure 
5.3d). The radio signal increased rapidly in the left P-LN from 3.5 %I.D./g at 12 min to 
9.8 %I.D./g at 62 min p.i. suggesting the fast and efficient lymphatic draining of NC20. 
As a comparison, negligible radio signal was detected in the right P-LN (0.66 %I.D./g at 
12 min and  1.9 %I.D./g at 62 min p.i.) indicating the localization of NC200 at the 
injection site. The amount of the accumulated NC20 in left P-LN kept increasing over 
time and reached the plateau at about 6 h p.i. (10.3 I.D.%/g) (Figure 5.3d). Such high 
level of lymphatic accumulation maintained as long as 24 h p.i. (10.4 I.D.%/g) suggesting 
that NC20 tended to retain in the lymph nodes presumably because the NCs were 
engulfed by the macrophages and dendritic cells in the lymph node.24, 35, 59 The right side 
of the mouse injected with NC200 showed substantially lower radio activity in the P-LN 
at 6 h and 24 h p.i. (1.3 and 2.7 %I.D./g respectively). The highest level of accumulation 
of NC200 in P-LN was reached at 24 h during the course of study which was much 
longer than NC20 (6 h). This observation revealed that 20-nm NP travels greatly faster in 
lymphatic system than the 200-nm counterpart. A 3D reconstructed image and movie 
(Figure 5.3c) also gives the evidence of the significantly enhanced accumulation of NC20 
in the left P-LN at 6 h p.i.. NC20 has about ~3.8 fold increase accumulation in P-LN as 
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Figure 5.4 Accumulation of NC20 and NC200 in P-LNs of C57BL/6 mouse 24 h post injection. 
The radioactivity in the extracted P-LNs was measured with γ-counter ex vivo (average ± SD; n=3; 
*p<0.05). Same amount of radioactivity of NC20 and NC200 was injected into each side. 
 
5.3.4. Fluorescence imaging using the dual-modal silica nanoconjugates  
As the silica NCs were also labeled with NIR dye, they provided the possibility for 
intraoperative guidance and LN imaging with higher resolution. To demonstrate the use 
of the integrated NIR fluorophore for fluorescence imaging, I harvested the inguinal 
lymph nodes (I-LNs) from both sides after the mice were sacrificed 24 h p.i. for ex vivo 
imaging with Odyssey infrared imaging system (Figure 5.5a, b). Significant fluorescence 
signal (298.9 a.u.) was observed in the I-LN of left side where the NC20 was injected, 
whereas negligible fluorescence signal (50.5 a.u.) was present in the right I-LN receiving 
the injection of NC200 (Figure 5.5c). The fluorescence measurement reveals that the 
NC20 has ~6 fold higher efficiency to migrate to remote LNs through the lymphatic 
vessels. This result again highlights the crucial role of NP size on its performance in 
lymphatic distribution and demonstrates that 20-nm NC is preferential for efficient 
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procedure for imaging sentinel LN) diffuse away too quickly and does not stay in LN for 
extended period of time.33, 60 Clearly, the size of nanoprobe plays a vital role in 
controlling the performance of NPs in lymphatic trafficking. NC20 can rapidly and 
efficiently accumulate in LNs most likely because of the effective passive diffusion from 
interstitial space into the lymphatic vessels due to the ultra-small size and efficient 
transportation to draining LNs once it is in the lymphatic vessels.32, 35, 61  However, 
NC≥100 nm in size is likely internalized by peripheral dendritic cells first and then taken 
to the LNs.32, 35, 61 This process usually takes more than 24 h, which could be the reason 
that there was a small increase of LN accumulation of NC200 at 24 h p.i. (Figure 5.3d). 
Our observation agrees with the recent reports by Wang et al. 36 and Reddy et al.35 that 
20-30 nm NPs can transport to LNs much more efficiently than 100-nm NPs after 
interstitial injection. The NP of 20 nm in size may also outperform the NPs of 30-50 nm 
and larger NPs in terms of efficient lymphatic uptake.29, 34, 35, 62 Even smaller NPs (ex. <8 
nm) may preferentially transport to the blood circulation and get clearly rapidly.30, 33 Thus, 
our 20-nm silica NC is likely in the optimum size range (10-20 nm) for the most efficient 
passive LN targeting.  
 
5.3.6. Synthesis of aptamer functionalized silica NCs 
Next, I functionalized the surface of NC20 with NCL-Apt to assess the targeting 
capability of Apt functionalized NCs for metastatic sentinel LN. Scheme 5.1 illustrates 
the conjugation of NCL-Apt to the surface-bounded PEG of silica NCs. The sequence of 
the NCL-Apt is 5'-GGT GGT GGT GGT TGT GGT GGT GGT GGT TTT TTT TTT 
TTT TTT TT/3ThioMC3-D/-3'. Poly-T sequence was employed as a spacer to allow the 
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recognition sequence to fully extend from the NC surface for the most efficient targeting. 
A control DNA (Ctrl-DNA) with a random sequence with the same spacer was also 
conjugated to NC20 as a comparison. The successful DNA conjugation was achieved 
with high efficiency (73.2 and 79.6% for Ctrl-DNA and NCL-Apt functionalized NC20 
(noted as NC20-Ctrl and NC20-Apt) respectively (Table 5.1)) and was evidenced by the 
slight increase of the hydrodynamic diameter measured by DLS (increase from 43.8±0.4 
nm to 59.6±0.4 and 63.5±0.3 nm for NC20-Ctrl and NC20-Apt respectively (Table 5.1)).  
 
5.3.7. Aptamer functionalized silica NCs for targeted imaging of metastatic lymph 
nodes 
 
Figure 5.6 In vitro 4T1 cell targeting with NC20-Apt. Internalization of NC20-Ctrl and NC20-
Apt by 4T1 cells over 2 h incubation at 37 °C was evaluated by a) the mean fluorescence of 
treated cells and b) the percentage of cells containing internalized NCs using flow cytometry. 
 
The targeting capability of NC20-Apt was first assessed in vitro. RITC labeled NC20-
Ctrl and NC20-Apt were incubated with 4T1 cells separately and the fluorescence of the 
treated cells were then analyzed with flow cytometry (Figure 5.6a). The result showed 
that there was 1.6-fold increase of mean fluorescence intensity in 4T1 cells treated with 
































































that 70.7% of the cells incubated with NC20-Apt for 2 h became fluorescently positive 
whereas only 57.5% for NC20-Ctrl (Figure 5.6b). The results clearly demonstrated that 
the Apt functionalized silica NC20 had enhanced binding ability toward 4T1 breast 
cancer cells in vitro. As the NC20-Apt can be selectively uptaken by the 4T1 cancer cells, 
I expect that more NC20-Apt will accumulate in metastatic LN, which has increased 
number of cancer cells, than normal LN. Then I further evaluated the in vivo targeting 
capability of the NC20-Apt to metastatic sentinel LNs. A metastatic LN tumor model was 
first established by hock inoculation of 4T1 murine breast cancer cells (stably transfected 
with firefly luciferase) on both legs of female BABL/c mice through interstitial 
injection.24, 54 After 8 days, visible primary tumors had developed and strong localized 
bioluminescent signal at injection sites were detected (Figure 5.7a,b). Tumor cells have 
also metastasized to the draining P-LNs as well, which was evidenced by the enlarged 
size and further histological analysis of the excised metastatic P-LNs (mP-LNs) (Figure 
5.7c, d).43, 63 To mimic the administration route of other SLN imaging agents, the NC20-
Ctrl and NC20-Apt were subcutaneously injected into the interstitial space between the 
primary tumor and the mP-LNs mouse (left: NC20-Ctrl; right: NC20-Apt) (Figure 5.8a). 
PET/CT images were acquired 24 h p.i. to compare the uptake of both NCs in mP-LNs. 
Clearly, much stronger PET signal was observed in the right mP-LNs injected with 
NC20-Apt (Figure 5.8b). The accumulation of NC20-Apt in mP-LN was ~2.3 fold higher 
than NC20-Ctrl by quantifying the radio signal in the PET images (6.2 and 14.6 %I.D./g 
for NC20-Ctrl and NC20-Apt respectively) (Figure 5.8c). This result was also confirmed 
by ex vivo measurement of the radioactivity in the mP-LNs using γ-counter (6.5 and 
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LN targeting strategy is surface decorating with sugar to enhance the uptake by 
macrophages which home to LN.64-67 However, macrophage which uptake the modified 
NP may also transport to blood circulation and eventually accumulate in other organs (ex. 
liver and spleen). Thus the selectivity of detection of metastatic LN could be low. 
Antibody41, 68 and peptide25, 40, 42, 43, 54 is also employed as active targeting ligand to 
modify the surface of nanoparticulate imaging probes to improve the targeting efficiency 
of metastatic LNs. However, the application of antibodies or peptides will be limited by 
their relative instability, high costs and difficulty to scale up. Therefore, the use of highly 
specific Apt functionalized silica NCs as imaging probes may unravel these issues and 
find applications in clinic settings.  
 
5.4. Conclusions 
In conclusion, I have successfully developed a PET/NIR dual-modal imaging probe based 
on precisely size-controlled silica NC for sentinel LN imaging. This dual PET/NIR 
imaging probe offers quite a few unique advantages comparing to conventional blue dye 
imaging for lymphatic system, for example, the use of PET overcome the depth-
insensitive issue of optical imaging tools; fluorescence imaging can compensate the 
relatively low resolution of PET image and potentially provide convenient intraoperative 
guidance. By controlling the size of dual-modal silica NC as small as 20 nm, I have 
demonstrated the rapid and effective LN accumulation for efficient LN imaging in vivo. 
For the first time, Apt was utilized as an active targeting ligand to functionalize the dual-
modal silica NC for lymphatic metastatic targeting. Significantly enhanced uptake and 
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(Figure 5.8 cont.) NCs was further confirmed by ex vivo measurement  of excised mP-LNs with 
γ-counter (average ± SD; n=3; *p<0.05). 
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CHAPTER 6  
BIOCOMPATIBILITY OF SILICA NANOCONJUGATE 
 
6.1. Introduction 
Nanomedicine, which integrates nanotechnology with medical applications, has 
developed rapidly in the last 2-3 decades.1-3 The goal of nanomedicine is to design and 
synthesize a drug delivery vehicle that can carry sufficient drugs, efficiently cross various 
physiological barriers to reach disease sites, and cure diseases in a less toxic and 
sustained manner. A large number of organic-materials-based nanomedicines, for 
example, liposomes, drug-polymer conjugates, polymeric micelles and nanoparticles 
(NPs), have been extensively studied as drug carriers for various biomedical applications. 
Each organic drug delivery system has its own advantages and disadvantages. For 
example, liposomes can easily load large amount of drugs to achieve high drug loadings,4 
but has intrinsically relatively low chemical stability, especially in harsh physiological 
condition. In addition to these organic drug delivery system, inorganic-materials-based 
system, such as gold NPs, quantum dots, silica NPs, iron oxide NPs, carbon nanotubes, 
etc., has emerged as promising alternatives to organic systems for a wide range of 
biomedical applications because of the unique characteristics for each system. Of the 
various materials explored, silica NP attracted especially great interest because of its ease 
and control of formulation and wide applications. Silica NP has a handful of advantages, 
for example, intrinsic hydrophilic surface for increase blood circulation, excellent 
biocompatibility of amorphous silica, versatile functionalization chemistry, ease of large-
scale preparation, and low cost, which make silica NP ideal candidate for development of 
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nanomedicines for a variety of diseases. However, as compared to organic-materials-
based nanomedicines, the toxicity profiles of silica NP as well as many other inorganic-
materials-based NP systems are not fully understood yet, which greatly prevents the 
medical application of these inorganic NPs in clinic.  
 
In Chapter 4 and 5, I have shown the applications of the precisely size controlled silica 
nanoconjugates (NCs) I developed in both cancer therapy and diagnosis, suggesting the 
great promise of this silica NC system future clinical translation. It is of tremendous 
interest to thoroughly investigate the biocompatibility of these bio-medically applicable 
silica NCs for in vivo systematic application in particular. To date, many in vitro 
evaluations of the toxicity of silica NP have been done.5-8 It is clear that the cytotoxicity 
of silica NP highly depends on the physic-chemical properties of silica NPs, for example, 
particle size, morphology, porosity, chemical purity, surface chemistry and solubility. 
The size of silica NPs was reported by many researchers to affect the cytotoxicity in 
vitro.9-13 Here, I have performed a series of studies to evaluate the systemic toxicity in 
vivo of intravenously administered silica NPs with precisely controlled sizes. The long 
term safety profile and clearance behavior was monitored in live animals. The results 
demonstrated that the silica NCs of different sizes (200, 50 and 20 nm in diameter) didn’t 
cause any acute or chronic toxicity to the mice and can be cleared from the mouse body 
over time.  
 




All NCs used here were prepared as described in Chapter 2. Blank silica NCs of different 
sizes and surface PEGylation were used to evaluate the cytotoxicity in vivo. 14C labeled 
acetic acid was purchased from PerkinElmer (Boston, MA, USA). The C-14 content of 
tissues was assayed in a Packard Tri-Carb 2100 TR Liquid Scintillation Analyzer 
(Downers Grove, IL, USA). Female C57BL/6 mice, aged 6 weeks (body weight 18-20 g), 
were purchased from Charles River, USA. Mice were housed in same-sex groups with 
three animals per cage. Feed and water was available ad libitum. All animals were 
quarantined for 1 week before the commencement of any experimental studies. The study 
protocol was reviewed and approved by The Illinois Institutional Animal Care and Use 
Committee (IACUC) of University of Illinois at Urbana Champaign. 
 
6.2.2. Preparation of 14C labeled silica NCs for long term clearance studies 
 
Synthesis of 14C-sil. In a reaction vial containing 3-aminopropyltriethoxysilane (1.6 mg, 
7.2 µmol) was added a methanol solution (0.5 mL) of 14C labeled acetic acid (~80 µCi, 
1.44 µmol) and EDC (13.8 mg, 72 µmol) and NHS (8.3 mg, 72 µmol). The reaction 
mixture was stirred for 12 h at RT. The solvent and triethylamine was removed by 
vacuum to give 14C-sil, which was used directly without further purification.  
 
Preparation of 14C labeled silica NCs of controlled sizes. The size controlled silica NCs 
were prepared as described in Chapter 2 except for addition of 14C-sil (~5 µCi for each 




















6.2.3. Cytotoxicity of blank silica NCs by MTT assay 
MCF-7 cells were seeded in 96-well plates at 3,000 cells/well and grown in culture 
medium containing 10% FBS at 37°C for 24 h in a humidified 5% CO2 atmosphere. The 
medium was replaced with fresh medium containing blank silica NCs (50 nm) in 
concentrations ranging from 1 µM to 10 mM of SiO2. At each concentration of six wells 
per plate were treated. The cell viability was determined by the MTT assay after 72 h. 
The standard MTT assay protocols were followed thereafter.14 
 
6.2.4. Experimental protocol of biocompatibility study 
Three female C57BL/6 mice for each group were given a 200-µL injection of either 
sterile PBS (1×) buffer or blank silica NCs with different sizes (200, 50 and 20 nm) at a 
single dose of 250 mg SiO2 NC/kg through intravenous injection (Table 6.1). Five sets of 
the experiments were set up in parallel to allow each set of animals to be sacrificed at five 
different time point (Day 1, Week 1, Week 2, Week 4, Week 8 post injection). Mice that 
were euthanized at Week 8 were carefully monitored throughout the study for the change 
of body weight (measured twice a week) and the average food intake for each mouse 
(recorded once a week). All mice were euthanized by carbon dioxide asphyxiation at set 
time points. Blood was collected via retroorbital bleeding for analysis of complete blood 
count (CBC) and blood chemistry (for the groups of Day 1, Week 1, Week 2, Week 4). 
The tissues and organs were excised and weighed accurately and processed for pathologic 
evaluation (for the groups of Day 1, Week 1, Week 2, Week 4, Week 8). The coefficients 
of liver, spleen and kidneys to body weight were calculated as the ratio of tissues (mg) to 




6.2.5. Hematology analysis and blood biochemical assay 
Blood samples were collected in tubes containing EDTA as anticoagulant. All the 
measurements were performed at Diagnosis Lab (Department of Veterinary Clinic 
Medicine, University of Illinois at Urbana-Champaign). I selected the following standard 
hematology markers for analysis: white blood cell count (WBC), red blood cell count 
(RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC),  
platelet count (PLT).   
 
Blood samples were centrifuged twice at 3000 rpm for 10 min in order to separate serum. 
Blood chemistry panel was also measured. In the present study, liver function was 
evaluated with serum levels of total bilirubin levels (TBIL), alanine aminotransferase 
(ALT) and alkaline phosphatase (ALP). Nephrotoxicity was determined by blood urea 
nitrogen (BUN) and creatinine (CRE). Albumin (ALB) was assayed as one parameter of 
damage of tissue or inflammation. Global parameters, including total protein (TP), 
cholesterol (CHOL), triglycerides (TRIG), phospholipids (PHOS), glucose (GLU) were 
also measured to determine any systemic toxicity.  
 
6.2.6. Histopathological examinations 
A complete postmortem examination was performed on each mouse, and each mouse was 
examined for gross changes Tissues recovered from the necropsy were fixed in neutral-
buffered 10% formalin, embedded in paraffin, sectioned, and stained with hematoxylin 
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and eosin (H&E) for histological examination using standard techniques at Diagnosis Lab 
(Department of Veterinary Clinic Medicine, University of Illinois at Urbana-Champaign). 
The slides were observed and photos were taken using optical microscope. All the 
identity and analysis of the pathology slides were blind to the pathologist. 
 
6.2.7. Clearance study 
Female C57BL/6 mice houses in metabolic cages (three mice per cage) with wire floors 
that allowed any feces produced to drop into a waste container. Each group was given an 
intravenous injection (200 µl) of 14C labeled silica NCs with different sizes (200, 50 and 
20 nm) at a single dose of 250 mg SiO2 NC/kg (0.4-0.6 µCi/each mice; Table 6.3). All 
the mice were euthanized by carbon dioxide asphyxiation at five different time points 
(Day 1, Week 1, Week 2, Week 4, Week 8 post injection). Blood and tissues were also 
collected as abovementioned. Accumulated feces and urines were also collected. All the 
collected samples were subjected for 14C radioactivity measurement to determine the fate 
of silica NCs. The C-14 content of tissues was assayed in a Packard Tri-Carb 2100 TR 
Liquid Scintillation Analyzer (Downers Grove, IL, USA). The tissues were solubilized in 
Solvable (Packard), and activity was counted in UltimaGold scintillation cocktail 
(PerkinElmer, Boston, MA, USA). The liver and intestine from each mouse was 
homogenized due to its large size, and ~100 mg of tissue was placed in a scintillation vial 
for analysis. Other organs were placed directly in scintillation vials. Each organ or blood 
(100 µL collected) was solubilized in 2 mL Solvable for 4 h at 60 °C, and the resulting 
solution was de-colored with 300 µL hydrogen peroxide for 1 h at 60 °C. To determine 
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100% dose, vials of the formulated NPs were counted along with the tissues. Data are 
presented as percent injected dose (mean ± SD). 
 
6.2.8. Statistical analyses 
Statistical analysis was performed using a Student’s t-test (two-tailed). The results were 
deemed significant at 0.01 < *p  0.05, and highly significant at 0.001 < **p  0.01. 
 
6.3. Results and discussion 
6.3.1. In vitro cytotoxicity of blank silica NCs 
The toxicity of blank silica NCs were first evaluated in vitro with several different cancer 
cells. IC50 values of blank silica NCs (50 nm) for all the cell lines tested (MCF-7, Figure 
6.1; Table 3.1 in Chapter 3) are larger than 1 mM (72 h continuous incubation with cells) 
indicating very low cytotoxicity. In the case of MCF-7 cells, only when the concentration 
was 10 mM of the blank silica NCs, the cell viability drop to 55.5±18.2%. Thus the in 
vitro toxicity of blank silica NCs is negligible in the tested concentration for the 
applications mentioned in Chapter 4 and 5. I will focus on evaluating the possible 







Figure 6.1 In vitro cytotoxicity of blank silica NCs (50 nm) to MCF-7 cells. Cell viability was 
measured by MTT assay and scaled to control (without treatment). 


















Table 6.1 Experimental protocol for the biocompatibility study.[a]  
 
[a] Three female C57BL/6 mice for each group were given a 200-µL injection of either sterile 
PBS (1×) buffer or blank silica NCs with different sizes (200, 50 and 20 nm) at a single dose of 
250 mg SiO2 NC/kg through intravenous injection. Five sets of the experiments were set up in 
parallel to allow each set of animals to be sacrificed at five different time point (Day 1, Week 1, 
Week 2, Week 4, Week 8 post injection).  
 
6.3.2. In vivo biocompatibility study of blank silica NCs of different sizes 
The single dose of silica NCs (250 mg/kg in 200 µL of PBS (1×), equal to the total dose 
used in the efficacy studies in Chapter 4) was administered to mice through tail vein 
injection (Table 6.1). Mice received 200 µL PBS (1×) served as control. This single dose 
was enough to achieve significant efficacy in the treatment of both primary and 
metastatic tumor as shown in Chapter 4. However, if significant toxic effects are 
observed with such dose of silica NCs, a graded dose-response analysis would be 
required. Five sets of the experiments were set up in parallel to allow each set of animals 
to be sacrificed at five different time point (from Day 1 up to Week 8 post injection) to 
investigate any possible long-term toxicity. During the whole study, there were no deaths 
and no changes were observed in the physical appearance (fur, eyes, mucous membranes, 
secretions, stool, gait, posture, breathing pattern), behavior (gait, posture, stereotypes, 
vocalizations), or social interactions of all mice. The increase of body weight of all the 
Group PBS 200 nm 50 nm 20 nm
Day 1 3 female 3 female 3 female 3 female
Week 1 3 female 3 female 3 female 3 female
Week 2 3 female 3 female 3 female 3 female
Week 4 3 female 3 female 3 female 3 female
Week 8 3 female 3 female 3 female 3 female
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mice receiving silica NCs of various sizes was similar as the mice PBS group and no 
significant difference was observed. Similarly, the average food intake for each mouse 
increased over time during the study following similar patterns and there was no 
statistical significance between any silica NC group and PBS group. These macroscopic 
observations revealed that the i.v. injected silica NCs (200, 50, 20 nm) did not cause any 
mortality or severe toxicity to the tested mice.  
 
Figure 6.2 Monitoring of body weight (a) and food intake (b) of the mice administered with 
blank silica NCs of different sizes. Data are presented as mean and standard deviation. (Student 
T-test (two-tailed): n.s., not significant, 0.01< *p ≤ 0.05; **p ≤ 0.01).  
 
After the mice were sacrificed at each time point, their organs were collected, weighed 
and further analyzed for histopathological examinations. Figure 6.3 shows the 
coefficients of the liver, spleen and kidneys to body weight which were expressed as 
milligrams (wet weight of tissues)/grams (body weight). No significant differences were 





























































group. Some slight increase (not significant) of the coefficients of spleen of the mice 
treated with silica NCs (200, 50, 20 nm) may suggest some effect of the injected silica 
NCs to the spleen of the tested mice.  
 
Figure 6.3 The coefficients of liver (a), spleen (b) and kidneys (c) to body weight (calculated as 
the ratio of tissues (mg) to body weight (g)) for the mice sacrificed at different time points. Data 
are presented as mean and standard deviation. (Student T-test (two-tailed): n.s., not significant, 
0.01< *p ≤ 0.05; **p ≤ 0.01).  
 
6.3.3. Hematology and blood biochemical assay 
To further evaluate any systemic toxicity, complete hematology analysis and blood 
biochemical assay was performed for all the tested groups at different time point. 
Representative hematology results indicated that all the measured factors were within 
normal ranges except for the platelet count measured at Day 1 (Figure 6.4; normal range 
was indicated by purple lines15). The decreased of the platelet count for all the groups 
including PBS group may be because of the artificial effect in the blood collection and 






































































was not relevant to the toxicity study of silica NCs. However, significant increase of 
WBC (Week 4) and RBC (Day 1) for the mice treated with 20-nm silica NCs as 
compared to PBS group was observed. This result may indicate the elevated activation of 
immune system in the mice treated with 20-nm silica NCs.16 Also, significant decrease of 
MCV and MCHC for the 20-nm NC (Week 4) and 50-nm NC (Day1) suggested that the 
small NCs (≤50 nm) may slightly negatively affect the red blood cells.  
 
Figure 6.4 Complete blood counts of C57BL/6 mice following injection of silica NCs of different 
sizes. The following standard hematology markers were analyzed: white blood cell count (WBC), 
red blood cell count (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume 
(MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration 












































































































(Figure 6.4 cont.) presented as mean and standard deviation. (*denotes statistical significance for 
the comparison of PBS group.*p < 0.05, two-tailed student T-test). 
 
 
Figure 6.5 Clinical Chemistry indexes of C57BL/6 mice following injection of silica NCs of 
different sizes. The following blood chemistry panel was measured: total bilirubin levels (TBIL), 
alanine aminotransferase (ALT), alkaline phosphatase (ALP), blood urea nitrogen (BUN), 
creatinine (CRE), Albumin (ALB), total protein (TP), cholesterol (CHOL), triglycerides (TRIG), 
phospholipids (PHOS), glucose (GLU). Normal range of each factor is indicated by purple line. 
Data are presented as mean and standard deviation. (*denotes statistical significance for the 
comparison of PBS group.*p < 0.05, two-tailed student T-test). 
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Table 6.2 Summary of histophathological examination results.[a]  
 
[a] Histopathological examinations of major organs excised from C57BL/6 mice following 
injection of silica NCs of different sizes. The following tissues were examined: heart, lung, spleen, 
kidney, liver, stomach, small intestine (small Int.), gut associated lymphoid tissue (GALT), 
pancreases, cecum, large intestine (large Int.) and mesenteric lymph node (MLN). NSC: no 
Time 
point Group Heart Lung
Splee
n Kidney Liver Stomach
Small 
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(Table 6.2 cont.) significant changes. M: missing tissues/organs. *a small focus of interstitial 
nephritis was found which would be clinically irrelevant and is probably unrelated to the study. 
 
Appearance and micro morphology of all the tissues were examined by independent 
pathologist in histophathological analysis (Figure 6.6 and Table 6.2). Detailed necropsy 
of the mouse did not reveal any gross organ abnormality or evidence of NCs in the heart, 
lung, kidney, stomach, small intestine (small Int.), gut associated lymphoid tissue 
(GALT), pancreases, cecum, large intestine (large Int.) and mesenteric lymph node 
(MLN). 
 
However, in the Gallbladder, minimal, multifocal neutrophilic infiltrates in the 
submucosa were noted in with 200nm NC (2/3 mice) and 20nm NC (1/3 mice). These 
neutrophilic infiltrates were not associated with any epithelial degeneration of the 
gallbladder. In the spleen of mice treated with 200-nm NCs (3/3 mice), minimal 
multifocal foamy macrophages aggregates were observed in the red pulp and at the 
periphery of the white pulp. These macrophages are characterized by microvacuolated 
cytoplasm; they are likely phagocytizing the nanoparticles.  
 
These foamy macrophages are commonly observed in nanoparticle toxicity studies and 
are likely a “foreign body” type reaction.17 These foamy macrophage aggregates were not 
observed in mice injected with 50 and 20nm NPs. The results indicated that smaller NCs 





Table 6.3 Experimental protocol for the clearance study.[a]  
 
[a] Each group was given an intravenous injection (200 µl) of 14C labeled silica NCs with 
different sizes (200, 50 and 20 nm) at a single dose of 250 mg SiO2 NC/kg (0.4-0.6 µCi/each 
mice).  
 
6.3.5. Clearance study of blank silica NPs of different sizes. 
The silica NCs of difference size were covalently labeled with 14C to trace the fate after 
administration in mice. The single dose of silica NCs (0.4-0.6 µCi/each mice) was 
administered to mice through tail vein injection (Table 6.3). At each time point, mice 
were sacrificed to collected blood and major organs to evaluate the amount of silica NCs 
remaining in the body. Accumulated feces and urine collected from metabolic cages were 
also were also measure for the cleared NPs. The methodology was verified with 
calibration curve for the radioactivity range of the samples and all the recovery efficiency 
for each organ (≥95%, Table 6.4 and Figure 6.9). The results at Day 1 showed that most 
injected NCs accumulated in liver (75.3±23.9, 56.5±5.0, 80.7±22.6 I.D.% for 200, 50, 20-
nm NCs respectively) and spleen (16.3±0.6, 16.3±6.0, 14.5±7.1 for 200, 50, 20-nm NCs 
respectively) (Figure 6.7). Small amount of NPs are in intestines and lung. More than 80% 
of injected NPs were cleared from body for the NPs of all the three sizes over time. The 
silica NCs in liver and spleen were gradually cleared overtime. The accumulated amount 
of silica NCs at Week 8 was 5.6±1.0, 0.90±0.05, 0.48±0.06 I.D.% in liver and 2.5±0.5, 
0.40±0.14, 0.22±0.02 I.D.% in spleen for 200, 50, 20-nm NCs respectively. And the 
Group 200 nm 50 nm 20 nm
Day 1 3 female 3 female 3 female
Week 1 3 female 3 female 3 female
Week 2 3 female 3 female 3 female
Week 4 3 female 3 female 3 female
Week 8 3 female 3 female 3 female
164 
 
accumulation of 50 and 20-nm NCs in liver and spleen was significantly lower as 
compared to 200 nm NCs. About 1~3 I.D.% of all the three NCs was continuously 
observed in intestine from Day 1 to Week 8, which may suggest the possible clearance 
pathway. It is also noticeable that 50 and 20-nm NCs has significantly higher amount in 
intestines than 200 nm NCs (Week 1 and Week 2). This could be the reason that 50 and 
20-nm NCs were cleared faster than 200 nm NCs. 
 
To compare the total amount of injected silica NCs remaining in the mouse body, the I.D.% 
in each organ/tissue was sum up (Figure 6.8). The total amount of silica NCs left in mice 
body at Week 1 was 62.8±6.2, 53.5±3.9, 61.6±3.9 I.D.% for 200, 50, 20-nm NCs 
respectively. These numbers decrease significantly to 8.9±1.7, 1.9±0.1, 1.8±0.2 I.D.%. 
The total accumulation of 50 and 20-nm NCs was significantly lower than 200 nm NCs, 
suggesting the faster clearance of the smaller NCs. Detectable amount of silica NCs was 
continuously found in the accumulated feces. The observation that intestine and feces 
contain radioactivity over that course of the study indicates that the silica NCs were very 
like cleared through the feces. These results gave clear evidence that the silica NPs can be 
cleared from body over time through the mice’s feces. Silica NPs are safe biomedical 





Figure 6.7 In vivo clearance studies. a to j: Biodistribution of 14C labeled silica NCs in liver and 


















































































































































































































(Figure 6.7 cont.) Week 4; i. j: Week 8). Data are presented as percent injected dose (mean ± SD). 
(Student T-test (two-tailed): n.s., not significant, 0.01< *p ≤ 0.05; **p ≤ 0.01).  
 
 
Figure 6.8 a. total amount of 14C labeled silica NCs left over in all the organ/tissues that were 
measured. Data are presented as percent injected dose (mean ± SD). b, accumulated amount of 
14C labeled silica NCs in feces. Data are presented as percent injected dose per gram of feces 
(mean ± SD). (Student T-test (two-tailed): n.s., not significant, 0.01< *p ≤ 0.05; **p ≤ 0.01). 
 
Table 6.4 Recovery efficiency for C-14 measurement by liquid scintillation counter. 
 




















































Figure 6.9 Calibration curve of the 14C measurement.  
 
6.4. Conclusions 
In this chapter, systematic toxicity evaluation was carried out for size controlled silica 
NCs in mice. Mortality, clinical features, monitoring of body weight and food intake, 
hematology and blood biochemical indexes and pathological examinations all revealed 
low in-vivo toxicity of silica NCs of different sizes (200, 50 and 20 nm). The long term 
safety profile and clearance behavior was monitored in live animals. The results 
demonstrate that the silica NC of different sizes does not cause any acute or chronic 
toxicity to the mice and can be cleared from mouse body over time. Generally, small NCs 
(≤50 nm) cause more significant effect on hematology and blood biochemical indexes but 
can be cleared from mouse body faster than larger NCs. 
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